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Parkinson's disease (PD), the second most common neurodegenerative disease, is 
caused by the progressive loss of dopaminergic neurons in the substantia nigra, 
accompanied by an alteration in the dopamine concentration in the striatum. 
Hydrogen sulfide (H2S), the newest member of the gasotransmitter family, serves as 
an important neuromodulator in regulation of the brain functions. The present study 
aimed to investigate the protective effect of H2
 The effect of H
S against cell injury induced by 6-
hydroxydopamine (6-OHDA), a selective dopaminergic neurotoxin often used to 
establish a model of PD. 
2S on neurotoxin, 6-OHDA was first examined. It was found 
that the exposure to 6-OHDA at 50-200 µM for 12 h decreased cell viability of SH-
SY5Y cells. Exogenous application of NaHS (an H2S donor) at 100-1000 µM or 
overexpression of cystathionine β-synthase (a predominant enzyme to produce 
endogenous H2S in SH-SY5Y cells) protected cells against 6-OHDA-induced cell 
apoptosis and death. NaHS (100 µM) also reversed the up-regulation of cleaved poly 
(ADP-ribose) polymerase (PARP) in 6-OHDA (50 µM)-treated cells. Furthermore, 
NaHS reversed 6-OHDA-induced loss of tyrosine hydroxylase, the rate-limiting 
enzyme for dopamine production. The underlying signaling mechanisms for H2S 
protection are associated with the activation of PKCα,ε and PI3K/Akt pathway. In 
addition, blockade of PKCα and ε with their specific inhibitors significantly 
attenuated NaHS-induced Akt phosphorylation, suggesting that activation of Akt by 
NaHS is PKCα, ε-dependent. 
viii 
 
 As endoplasmic reticulum (ER) stress has been indicated as a potential 
mediator of PD, the effect of H2
In conclusion, the present study demonstrate for the first time that H
S on 6-OHDA-induced ER stress was also examined 
in this study. Consistent with its cytoprotection, NaHS markedly reduced 6-OHDA- 
induced ER stress responses, including up-regulation of phospho-eIF2α, BiP mRNA 
level and CHOP protein expression level. The protective effect of NaHS against ER 
stress was mediated by Akt and Hsp90. Interestingly, a decrease in the levels of 
Hsp90 upon inhibition of Akt activity was observed, suggesting that activation of Akt 
by NaHS may stimulate Hsp90 protein expression. 
2S may 
protect against cell injury and ER stress induced by 6-OHDA neurotoxin via multiple 
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CHAPTER 1 INTRODUCTION 
 
1.1 General Overview 
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
affecting the elderly and is characterized by progressive loss of dopaminergic neurons 
in the substantia niagra, accompanied by the alteration of dopamine concentration in 
the striatum [1]. Despite years of intensive research, its etiology remains elusive 
although several mechanisms have been demonstrated as crucial to PD pathogenesis: 
oxidative stress, generation of reactive oxygen species (ROS), endoplasmic reticulum 
(ER) stress and apoptosis [2-5]. These pathogenic mechanisms may act 
synergistically and be held responsible to promote PD [6].  
Paradoxically known as an environmental pollutant, H2S is now widely 
recognized as a novel “gasotransmitter”, produced naturally in mammalians. H2
7
S has 
been categorized as the third endogenous gaseous mediator alongside nitric oxide 
(NO) and carbon monoxide (CO) as they share similar properties: small gaseous 
molecules; membrane permeable; do not act via specific membrane receptors; and are 
produced enzymatically [ ]. H2S could be generated in many mammalian cells with 
L-cysteine as substrate and functionally, H2
7-13
S has been implicated in regulating many 
bodily functions [ ]. The turning point started in 1996 when Abe and team first 
describe H2S as an important endogenous neuromodulator and subsequently in 2004, 
H2 12S was found to be a neuroprotectant against oxidative stress [ , 14]. These two 
key findings have opened up a whole new area in exploring the important roles of 
H2S in regulating the central nervous system (CNS) functions.  
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For the past decade, researchers have shown growing interest in the 
physiological and pathological functions of H2
15
S in many systems, which varies from 
the brain to the gut [ ]. However, the role of H2S in neuroprotection against PD has 
not been documented. Therefore, this thesis was designed to investigate the potential 
role of H2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
S on 6-hydroxydopamine (6-OHDA)-induced cell death and endoplasmic 
reticulum (ER) stress in human dopaminergic neurons.   
1.2 Parkinson’s disease (PD) 
First described by British physician, James Parkinson in 1817 as paralysis agitans or 
the ‘shaking palsy’ [16], Parkinson’s disease (PD) is now the second most common 
age-related neurodegenerative disorder after Alzheimer’s disease (AD). PD patients 
suffer from bradykinesia, ridigity, resting tremor, slowing of movement and postural 
instability [17, 18]. Several non-motor symptoms are also common such as 
swallowing and speech, which seriously affect the quality of life. Apart from motor 
deficits symptoms, some patients with PD also exhibit cognitive dysfunction. In 
extreme cases, PD individuals suffer from dementia. Also in about 40% of PD 
patients, depressive symptomatology has been recognized [17, 18].  
PD is a result of progressive loss of dopaminergic neurons in the substantia 
nigra pars compacta (SN), accompanied by an alteration of dopamine concentration in 
the striatum [1]. The aetiology remains incompletely elucidated, although oxidative 
damage, generation of reactive oxygen species (ROS) [19], mitochondrial 
dysfunction, misfolded protein aggregation, ubiquitin-proteasome system (UPS) [20] 
and endoplasmic reticulum (ER) stress [4, 21, 22] might be responsible for its 
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pathogenesis. At present, levodopa (L-Dopa) is widely used as a treatment to restore 
dopamine concentration in PD patients [23]. However, long-term usage of L-Dopa 
does not arrest the progress of PD and long term treatment will induce side effect 
like dyskinesia [24-26] and accelerate the neuron degeneration due to the 
enhancement of oxidative stress [27-30]. 
 
Therefore, it is of great importance to 
understand the cause of PD as it could help to develop new potent therapies for PD.  
1.2.1 Epidemiology 
PD is the second most common neurodegenerative disease after Alzheimer’s disease. 
According to National Institutes of Health’s fact sheet updated in October 2010, 
about half a million people worldwide have been diagnosed with PD and 
approximately 50,000 new cases are diagnosed each year in the U.S.  
(http://report.nih.gov/NIHfactsheets/View Fact Sheet.aspx?csid=109). In the local 
context, according to Singapore Health Services (SingHealth), PD occurs in 
Singaporean as commonly as in the West. Three out of every thousand individuals, 
aged 50 years and above, have this disease (http://www.singhealth. 
com.sg/PatientCare/ConditionsAndTreatments/Pages/Parkinsons-Disease-Movement-
Disorders.aspx).  
 PD is an age-related disease. It is rare before age 50 years and the prevalence 
increases from 1% in people over 60 years of age, up to 4% in those over 80 years of 
age [31]. The mean age for PD onset is around 60 years of age, although there are 
about 5-10% cases whereby the onset of PD is at a much earlier age, which is 
between 20 and 50 [32].  
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Some studies have proposed that PD may be more prevalent in men than in 
women [31, 33], although other studies have failed to identify significant differences 
between these two genders [31]. Oestrogen as the source of neuroprotection has been 
suggested as a possible explanation for a lower risk in women than in men, but their 
role is still controversial [31]. Apart from that, issue of ethnicity in relation to 
occurrence of PD addressed that PD might be less prevalent in African and Asian 
ancestry compared to Caucasians. This finding is however, conflicting as the 
differences could be contributed by differences in response rates, survival and case-
ascertainment [31].  
 
1.2.2 Risk factors  
Some researchers speculated that genetic or environmental factors may contribute to 
PD neuronal damage while other researchers labeled it as idiopathic (unknown cause). 
No one primary cause of PD is yet to be identified, although several risk factors are 
clearly evident. 
Advancing age is one of the main risk factors of PD. Young adults rarely 
experience PD although it is not impossible to develop PD at an earlier age. PD 
generally manifests itself in the middle to late years of life. The risk continues to 
increase as one grows older.  
PD is heritable. Reseachers have demonstrated that mutated parkin [34], 
PINK1 [35], DJ-1 [36] and α-synuclein [37] genes are directly associated with early 
onset of PD. Therefore, individuals with siblings or parents who developed 
Parkinson's at a younger age are at higher risk for PD.  
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Ongoing exposure to toxins such as pesticides and herbicides puts one at a 
greater risk to PD. Some of the pesticides contained rotenone which inhibit dopamine 
production and promote free radical damage. Those involved in farming are therefore 
having a greater prevalence of Parkinson's symptoms. 
 Oestrogen is postulated to have neuroprotective effect and declining oestrogen 
level may increase the risk of PD. Post menopausal who do not use hormone 
replacement therapy are at greater risk, as are those who have had hysterectomies. For 
this reason also, it is theorized that males are more likely to get PD than females. 
 
1.2.3 Pathology and pathogenesis 
1.2.3.1 Pathology 
PD is a progressive neurological disorder that results from irreversible degenerative 
processes of dopaminergic neurons of the nigrostriatal pathway [38], resulting in 
marked motor control impairment. Symptoms of PD become obviously manifested 
when approximately 80% of dopamine levels in the striatum are lost [39], with 40-
50% reduction of the dopaminergic neurons in the substantia nigra (SN) pars 
compacta [18, 40].  
As the terminals of dopaminergic neurons degenerate, dopamine uptake is 
also reduced. However, given the inherent redundancy in dopamine terminals and 
dopamine receptors, active compensatory is possible to permit the striatal function to 
continue without disruption during early phases of neurodegenerative process [41]. 
Neurologic deficits become apparent when the availability of dopamine falls below 
the required level for compensation or when the system is subjected to certain 
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pharmacologic, environmental or physiologic challenges. With several groups of 
dopaminergic neurons in the central nervous system (CNS), it is the loss of the 
dopaminergic neurons in the SN that account for the motor manifestation of PD [42].  
Interestingly, in most cases neuronal loss is not only restricted to dopaminergic 
neurons. Loss of cholinergic neurons of the nucleus basalis of Meynert, may be 
responsible, at least in part, for dementia [43].  
A relatively specific pathological feature accompanying the neuronal 
degeneration in PD is an intracytoplasmic inclusion body, known as the Lewy body. 
In almost every case of PD, Lewy body is detected in pigmented neurons of the 
substantia nigra (SN) [44].  Other than the SN, localization of Lewy bodies in PD 
patients has been found in many areas, including the SN, locus ceruleus, nucleus 
basalis, hypothalamus, cerebral cortex, cranial nerve motor nuclei and the central and 
peripheral divisions of the autonomic nervous system [37].  
A Lewy body is composed of the protein α-synuclein associated with other 
proteins such as synphilin [45] and ubiquitin [46]. Mutations  (A30P or A53T) or 
triplications of α-synuclein  have been detected in some familiar PD patients, 
suggesting that mutations may disrupt the normal conformation of this protein, 
leading to aggregation [47-49]. Further investigation also indicated that the A30P and 
A53T mutants exhibit a higher potential to form oligomers and Lewy body-like fibrils 
than wild-type α-synuclein [50]. Wild-type α-synuclein is also found in Lewy body 
inclusions in sporadic PD patients, although the mechanism still remains unclear. It 
was speculated that the aggregation of wild-type α-synuclein was associated with the 
dysfunction of mitochondria complex-I [51-54], tyrosine nitration [55] and the failure 
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of proteasome function [56, 57]. The presence of α-synuclein has been reported to 
activate microglia, generating extracellular superoxide and increasing intracellular 
ROS [58], and thus potentiating neuronal death [59]. 
 
1.2.3.2 Pathogenesis 
The pathogenesis of both familial and sporadic PD remains incompletely elucidated, 
although oxidative stress and generation of reactive oxygen species (ROS) from 
dopamine metabolism, neuroinflammation, and mitochondrial impairment as well as 
protein aggregation and misfolding might be responsible for it pathogenesis. No one 
mechanism appears to be primary in all cases of PD and these pathogenic 
mechanisms may act synergistically through complex interplay to promote 
neurodegeneration as depicted in Figure 1.1. Hence, it is the combination of these 
contributing factors and dopamine oxidation enhances the vulnerability of 
dopaminergic neurons in the nigrostriatal tract and thus leads to the 
neurodegeneration in PD.  
 
Oxidative stress and mitochondrial dysfunction 
Oxidative stress results from the presence of overabundance of the reactive oxygen 
species (ROS) due to overproduction of ROS or inability of the biological system to 
readily detoxify the reactive intermediates. Dopamine can be auto-oxidized to forms 
quinones, semiquinones, neuromelanin as well as superoxide, including H2O2 and 
60reactive hydroxyl radicals [ , 61]. The rich in iron nature of SN provides abundant 
ferrous or cupric ions to catalyze the formation of highly reactive hydroxyl radicals 
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from H2O2 62 [ ]. Presence of neuromelanin metabolites alter the ability of the metal 
ions and enhance the participation in ROS production [63]. Mitochondrial 
dysfunction is another source for ROS production. Although the mechanisms 
responsible for mitochondrial dysfunction is not well understood, inherited or 
acquired mutations in mitochondrial DNA might contribute to its dysfunction [64-66]. 
Autopsy has found disminishing activity of mitochondrial complex I in PD patients 
[67], while Parkisonian mimetics neurotoxins induced complex I inhibition in animal 
models [51, 68, 69]. On top of that, anti-oxidant glutathione proteins are found to be 
reduced in postmortem PD nigra [70-72]. Researchers have also found that mutation 
in PTEN-induced putative kinase (PINK1) and DJ-1 genes reduce protection against 
oxidative stress [35, 73-75].  
 
Neuroinflammation 
Neuroinflammation is characterized by the release of proinflammatory cytokines and 
free radicals that can be provoked by injury to the brain. Neuroinflammatory 
responses are mediated largely by glial cells [76, 77], namely the actived microglia 
[78] and to a lesser extent, reactive astocytes [79]. Microglia, as the major contributor 
of proinflammatory and neurotoxic factors, are a specialized form of macrophage 
residing in the CNS. In 1988, McGeer and co-workers reported the presence of 
activated microglia within the substantia nigra of patients with PD at post-mortem 
[78]. Another group, Bertrand and co-workers found mild microglial activation in the 
locus coeruleus [80]. Activation of microglia in PD is poorly understood, although 
substances produced by dying dopaminergic neurons, which includes α-synuclein 
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aggregates [58], neuromelanin [81], adenosine triphosphate (ATP) [82] and matrix 
metalloproteinase-3 (MMP-3) [83] can promote microglia activation. Microglia, 
when activated in the presence of activating stimuli, produce and release various pro-
inflammatory factors such as nitric oxide (NO) superoxide [84], tumor necrosis 
factor-α (TNF-α) [85], interferon γ (IFN- γ) [86] and interleukin-1β (IL-1β) [87], 
which could in turn activate the neighboring microglia, leading to a feed forward 
cycle aggravating neuroinflammatory processes [88] and irreversible destruction of 
SN dopaminergic neurons [89].  
 Of note, reports have also suggested that the density of astrocytes is lower in 
the SN of PD patients. Evidences has shown that PD patients have fewer surrounding 
astroglial cells, which function to detoxify oxygen free radicals by glutathione 
peroxidase in healthy indivuals [79, 90]. This limited astroglial environment might 
also be a contributing factor in PD .  
 
Protein aggregation and misfolding  
Following gene transcription and translation, newly synthesized proteins are folded to 
achieve native conformations. However, even when natively folded, proteins have a 
low margin of stability and are constantly exposed to damaging conditions including 
temperature elevation and various post-synthetic modifications (e.g., oxidation, 
glycation, and nitrosylation) that could promote their denaturation or in worst case, 
accumulate and promote neurodegenerative diseases [91]. 
 As in the case of autosomal dominant familial PD, it was found that α-
synuclein, a major component of Lewy body, misfolded. Three missense mutations 
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(A30P, E46K and A53T) were found in the α-synuclein gene [37, 47]. Point mutation, 
overexpression and gene triplication, as well as oxidative damage to α-synuclein 
promotes self-aggregation and fibrillization of α-synuclein leading to neuronal 
dysfunction and dopaminergic neuronal death [92, 93]. Fueling this excitement is the 
identification of another PD-linked gene, parkin, an E3 ubiquitin ligase involved in 
targeting misfolded proteins for degradation . Like α-synuclein, parkin is also prone 
to misfolding and mutation in the parkin, as found in the genetic forms of PD, disrupt 
its E3 ubiquitin ligase activity, causing accumulation and aggregation of misfolded 
protein [22, 94, 95].   Similarly, protein misfolding may also affects other functions of 
PD-linked genes such as PINK1 and DJ-1 [96]. Henceforth, overexpression of the 
mutant genes lead to accumulation of unfolded proteins in the lumen of the 
endoplasmic reticulum (ER), creating an ER stress environment 
 
Endoplasmic reticulum (ER) stress 
The endoplasmic reticulum (ER) is a sophisticated luminal network for the synthesis, 
maturation, folding and transportation of proteins destined for cell membrane, Golgi 
apparatus, lysosomes, secretion and etc [97, 98]. Proper protein folding is essential in 
ensuring cellular functioning. General perturbations including glucose deprivation, 
inhibition of protein modification, disturbances of Ca2+
99-101
 homeostasis as well as 
accumulation of unfolded or misfolded proteins in the ER are a threat to cell survival 
[ ]. In order to withstand such potentially lethal conditions, ER stress response 
are activated [101] by triggering the cellular unfolded protein response (UPR) [44]. 
The UPR include translational attenuation, induction of ER resident chaperones, and 
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degradation of misfolded proteins through the ER-associated degradation (ERAD). 
Upon switching on the UPR-associated signal transduction events, the cells work 
towards re-establishing normal ER function. However, when the primary insult 
causing ER stress is protracted or excessive, cell death is initiated through apoptosis 
[52, 53, 57, 102].   
 Recent evidence has indicated endoplasmic reticulum (ER) stress as a 
potential mediator of PD [4, 22, 103] and in fact in several other diseases as well, 
such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS),  Huntington's 
disease (HD) and prion-related disorders (PrDs). These neurodegenerative diseases 
share a common neuropathology feature associated with abnormal formation of 






Figure 1.1 Schematic paradigms for multiple factors involved in ER stress in the 
pathogenesis of PD. In PD, oxidative stress, neuroinflammation, mitochondrial 
dysfunction, genetic mutation in parkin, PINK1 and DJ-1 could directly or indirectly 
cause accumulation of unfolded or misfolded proteins in the ER, thereby inducing ER 
stress. Cells respond to ER stress by activating the UPR-associated signal 
transduction events, re-establishing normal ER function. However, when UPR fails to 
eliminate misfolded protein and restore normal ER function, cells undergo apoptosis.   
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1.2.4 Clinical features and diagnosis 
PD is a chronic, progressive neurological disease. It is generally undetectable and by 
the time symptoms appear, about 50% of dopaminergic neurons in the SN has 
degenerated [18]. The symptoms affecting an individual patient is unpredictable and 
the intensity of the symptoms is distinctly individual. Although symptoms may vary 
among patients, the disease commonly includes 4 to 6 Hz resting tremor of one or 
more limbs, muscle rigidity, postural instability and bradykinesia [109]. 
 As there is no blood nor laboratory test available yet to help in diagnosing 
sporadic PD, most diagnosis is based on medical history and neurological 
examinations.  An accurate and precise diagnosis is difficult and early signs and 
symptoms of PD may sometimes be dismissed as the effects of normal 
aging. Physicians may sometimes request brain scans or laboratory tests in order to 
rule out other diseases. However, computerized tomography (CT) and magnetic 
resonance imaging (MRI) brain scans of individual with PD usually appear 
normal.  Therefore, underdiagnosis and misdiagnosis of PD is quite common with the 
most misdiagnosed cases including progressive supranuclear palsy (PSP), multiple 
system atrophy (MSA) and Alzheimer's disease [110]. A definitive diagnosis can be 
only made after autopsy. 
 
1.2.5 Treatment 
At the present, there is no cure for PD, but a variety of medications and surgery are 
available to provide dramatic relief from the symptoms. Table 1.1 summarizes the PD 
treatments available today.   
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Levodopa (L-Dopa)  
Recognition of loss of dopamine cells in PD led to development of the drug L-3,4-
dihydroxyphenylalanine, or known as Levodopa (L-Dopa). It is a simple compound 
derived from plant and animals. L-Dopa is suitable to treat PD as it can cross blood-
brain barrier (BBB), converted into dopamine and replenished the brain's dwindling 
supply. Dopamine pills itself cannot be given to the patients as it could not cross the 
BBB [111]. Usually, L-Dopa is prescribed together with another drug called 
carbidopa. When added to L-Dopa, carbidopa delays the conversion of L-Dopa into 
dopamine until it reaches the brain. Having done so, carbidopa also reduces the 
amount of L-Dopa needed in PD treatment [112].  
 Although L-Dopa can reduce the PD symptoms, it is not a cure. It does not 
replace the lost nerve cells nor stop the progression of PD [113]. L-Dopa-long term 
treatment can sometime cause hallucination and psychosis. Long term usage of L-
Dopa induces side effects including uncontrolled twitching movements (dyskinesia
24-26
) 
[ ], “on-off” fluctuations in symptoms control as well as 
 
accelerate neuronal 
degeneration due to the enhancement of oxidative stress [28, 30].  
Monoamine oxidase B (MAO-B) inhibitors 
Monoamine oxidase B (MAO-B) enzyme breaks down dopamine in the brain. 
Therefore, MAO-B inhibitors act to accumulate dopamine in the surviving nerve cells 
and reduce the PD symptoms. Selegiline is an irreversible MAO-B inhibitor most 
commonly used. It reduces dopamine oxidation by inhibiting the MAO-B enzyme and 
thus delay the disease progression for up to a year or more. However, one 
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disadvantage of selegiline relates to its metabolism to L-methamphetamine and L-
amphetamine which has been associated with cardiac and psychiatric effects in some 
patients. Selegiline may induces several side effects including nausea, orthostatic 
hypotension (drop in blood pressure), hallucination and insomnia. It may also worsen 
existing psychosis and dyskinesia (side effects of L-Dopa) [114, 115]. 
 In May 2006, rasagiline, a newer and more potent irreversible MAO-B 
inhibitor than selegiline, is approved by the U.S. Food and Drug Administration to be 
used along with L-Dopa for PD treatment. Rasagiline possesses metabolites with 
potential anti-oxidant properties and is metabolized to 1(R)-aminoindan instead of 
metamphetamine and/or amphetamine [115-117].  
 
Dopamine agonists 
Bromocriptine, apomorphine, pramipexole and ropinirole are examples of dopamine 
agonists available today [118-121]. These dopamine agonist drugs are not changed 
into dopamine inside the brain. Instead, they mimic the role of dopamine inside the 
brain and allow the brain neurons to act as if sufficient amounts of dopamine were 
present. Dopamine agonists may be used along with L-Dopa therapy. In younger 
adults, dopamine agonists may be used instead of L-Dopa. The side effects of 
dopamine are almost similar to that of L-Dopa, causing orthostatic hypotension, 
hallucinations, sleepiness, and confusion, although it is less likely to cause 




Catechol-O-methyltransferase (COMT) inhibitors 
Catechol-O-methyltransferase (COMT) is another enzyme, apart from MAO-B, that 
helps to break down dopamine. Two COMT inhibitors, the entacapone and tolcapone, 
have been approved to treat PD in the United States. These drugs act to prolong the 
effects of L-Dopa by preventing the breakdown of dopamine, thus reducing the dose 
of L-Dopa in PD treatment. The most common side effect is diarrhea.  The drugs may 
also cause nausea, insomnia, coloured urine, dizziness, abdominal pain, low blood 
pressure, or hallucinations.  In severe cases, tolcapone can cause liver 
disease.  Therefore, patients on tolcapone medication need regular monitoring of their 
liver function [123, 124].  
 
Deep Brain Stimulation (DBS) 
In some cases, surgery is appropriate when drug therapies are no longer sufficient. A 
therapy known as deep brain stimulation (DBS) has been approved by the U.S. Food 
and Drug Administration in 2002. In DBS, electrodes are surgically implanted into 
part of the brain. The electrodes are connected by a wire under the skin to a small 
pulse generator implanted in the chest beneath the collarbone and can be externally 
programmed. The pulse generator and electrodes painlessly stimulate the brain in a 
way that helps to alleviate many of the symptoms of PD.   
 DBS is primarily used to stimulate one of three brain regions:  the subthalamic 
nucleus, the globus pallidus, or the thalamus.  However, the subthalamic nucleus, a 
tiny area located beneath the thalamus, is the most common target.  Stimulation of 
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either the globus pallidus or the subthalamic nucleus can reduce tremor, bradykinesia, 
and rigidity.  Stimulation of the thalamus is useful primarily for reducing tremor.   
 While DBS therapy may reduce the need for L-Dopa and related drugs, which 
in turn decreases dyskinesia and relieves the "on-off" fluctuation of symptoms, it does 
not help with speech problems, posture, balance, anxiety, depression, or dementia. 
DBS does not stop PD progression, and some problems may gradually 
return.  However, studies have shown that patients who had had DBS surgeries are in 
better conditions than they were before undergoing DBS [125, 126].  
 
1.2.6 6-hydroxydopamine (6-OHDA) experimental model 
6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin widely 
used for over 30 years in experimental models of PD [127]. 6-OHDA shares some 
similar molecular structure to that of dopamine and norepinephrine, showing high 
affinity for the dopamine and norepinephrine transporters. Consequently, 6-OHDA is 
auto-oxidized, generating massive free radical species to inflict damages on the 
catecholaminergic pathways and selectively killing the dopaminergic and 
noradrenergic neurons [128]. 
Several groups including our group has demonstrated that 6-OHDA induce 
cell death in human neuroblastoma SH-SY5Y [129, 130] and mouse 
pheochromocytoma PC12 cell lines [131] as well as in rat models [132]. More 
importantly, 6-OHDA selectively kills tyrosine hydroxylase (TH) positive neurons in 
the SN and striatum of PD rat models [132], reducing the presence of TH rate-
limiting enzyme for the conversion of tyrosine to dihydroxyphenylalanine (DOPA), a 
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precursor for dopamine production [133]. The underlying cellular and molecular 
mechanisms in 6-OHDA-induced neuronal loss remains unclear, although auto-
oxidation and generation of reactive oxygen species (ROS) might be responsible for 
the dopaminergic death [134]. 6-OHDA also affects the mitochondrial function by 
inhibiting the activity of the electron transport chain by blocking complex I and IV, 
and thus activating the apoptotic cascades, such as caspase-3 activation and cleavage 
of PARP [135]. Recently, 6-OHDA is also shown to induce endoplasmic reticulum 
(ER) stress and activate the UPR in cultured neuronal PC12 cells [4]. Pro-longed and 
excessive ER stress and activation of the UPR signaling components have been 
reported to participate in the killing of dopaminergic neurons [4, 50].  
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Table 1.1  
 
Various treatments for Parkinson's disease 





Increasing dopamine level in the 
brain 





Selegiline Reducing dopamine oxidation by 
inhibiting MAO-B enzyme 
Nausea, insomnia, hallucinations, orthostatic 





Bromocriptine Mimicking the role of dopamine 
inside the brain 






COMT inhibition Entacapone  Reducing dopamine oxidation by 
inhibiting COMT enzyme 
Diarrhea, nausea, insomnia, colored urine, dizziness, 
abdominal pain, low blood pressure, hallucinations, 
liver disease (Tolcapone) 
[123, 124] 
Tolcapone 
Surgery Deep brain 
stimulation (DBS) 
Stimulate subthalamic nucleus, the 
globus pallidus, or the thalamus to 
reduce tremor, bradykinesia and 
rigidity 
Does not help with speech problems, posture, balance, 




1.3 Hydrogen sulfide (H2
It has been 300 years since the first description of H
S)  
2 136S toxicity in 1713 [ ].  Most 
studies carried out then were devoted to the toxic effects of H2
137
S rather than its 
physiological function [ ].  However, in 1989 and 1990, H2
138-140
S was discovered to be 
produced in the brains of rats, humans and bovine [ ]. Further investigation 
found that in mammalian cells, endogenous H2
8
S can be formed from cysteine by 
pyridoxal-5'-phosphate-dependent enzymes (cystathionine β-synthase (CBS) and 
cystathionine γ-lyase (CSE)) [ ] and by pyridoxal-5'-phosphate-independent enzyme 
(3-mercaptopyruvate sulfurtransferase (3MST)) in combination with cysteine 
aminotransferase (CAT) [15].     
 Subsequently over the years, endogenous H2
141
S has been found to play 
important roles in numerous physiological and pathological processes such as blood 
pressure regulation [ , 142], neurotransmission [12], anti-inflammation processes 
[143], and etc. Therefore, in the following context, recent studies on H2
 
S will be 
reviewed with an emphasis on its biological role in mammalian tissues. 
1.3.1 Physical and chemical properties of H2
H
S 
2S is a colourless, flammable, water soluble gas characterized by an offensive 
“rotten egg” odour. With a structural formula of H-S-H, H2S has a similar structure to 
that of water (H2O). However, as sulfur is not nearly as electronegative as oxygen, 
therefore, hydrogen sulfide is not as polar as water. With weaker intermolecular 
forces, H2S has a much lower melting and boiling point than water. H2S melts and 
boils at -85.5ºC and -60.7ºC respectively. H2S has a molecular weight of 34.08 which 
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makes it slightly denser than the air of the same temperature and hence tends to cause 
H2S to accumulate in low-lying, poorly ventilated areas such as the basements or 
manholes. The solubility of H2
144
S in water varies from 5.3 g/L at 10ºC to 3.2 g/L at 
30ºC [ , 145]. It is weakly acidic as H2S dissociates in the following sequential 
reactions: H2S ⇔ H+ + HS- ⇔ 2H+ + S2- 7[ ]. According to the standard Henderson-
Hasselbach calculation, at 20ºC and pH 7.4, H2S exists as 30-33% H2S and 67-70% 
HS- with negligible S2- due to its high pKa2 (>12). However, at 37ºC and pH 7.4, 
there is approximately only 18.5% (one fifth) H2S and 81.5% (four fifths) HS- 
146
in a 
physiological saline [ ]. This variation is because at 37ºC, the pKa1 is 6.76 while 
pKa1 at 20ºC is 7.04. These calculations have suggested that H2S solubility decreases 
as temperature increases. In lipophilic solvents, H2
7
S has solubility approximately 
fivefold greater than in water [ ] which enables it to freely penetrate the plasma 
membrane of all cell types and become biologically active.  
 As it is unlikely to determine which form of H2S (H2S, HS-, S2-
15
, or the 
mixture of free organic sulfides) is active, the term “hydrogen sulfide” has been used 
to refer to the sum of the aforementioned forms [ ].  
 
1.3.2 Toxicology of H2
Living up to its infamous description as a toxic gas, H
S  
2S is a broad-spectrum poison, 
intoxicating various body systems, among which the nervous system is the most 
affected. The toxicity of H2
147
S is comparable to that of hydrogen cyanide as both 
inhibit cytochrome oxidase c [ , 148]. In addition, recent studies found that H2S-
cytotoxic mechanisms involve cytochrome P450 (CYP450) and its isozymes, CYP 
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2E1, in forming reactive sulfur species (RSS) and reactive oxygen species (ROS) 
respectively [149, 150]. Together, these mechanisms prevent cellular respiration and 
hence cause respiratory paralysis. 
Since H2S occurs naturally in the body, there are enzymes in the body which 
are capable of detoxifying it. For example, in human colon, colonic mucosal 
rhodanese acts to detoxify H2 151S generated by anaerobic bacteria [ ], lowering the 
risk of inflammation, ulcerative colitis and  colorectal cancer [152, 153]. With these 
inner body protective enzymes, low levels of H2
H
S may be tolerated indefinitely.  
2S can be found naturally in crude petroleum, natural gas, volcanic gases, 
hot springs, manure as well as coal pits. It is also a by-product of petroleum refinery, 
pulp and paper manufacturing and carbon disulfide production. Either naturally 
occurring or a result of human activity, exposure to and inhalation of H2S could be 
health hazardous. At low concentration, H2S is odiferous and annoying. At times, it 
may cause headache, dizziness, eye irritation, shortness of breath, and upset stomach. 
On the other hand, at high concentration, H2
154-157
S poisoning may cause loss of 
consciousness and could be lethal [ ]. For survivors of sulfide poisoning, 
memory loss is common. A summary of human health effects due to exposure to H2
Human nose is sensitive to the pungent smell of H
S 
is presented in Table 1.2. 
2
154
S and could detect its 
unsavory smell as low as 0.02 ppm [ , 155]. However, odour should not be used as 
a warning sign of exposure to H2S since at higher concentration (up to 100 ppm), 
H2
156
S may deaden the sense of smell by paralyzing the respiratory center and olfactory 




Human health effects at various H2S concentrations 
Exposure (ppm) Health hazards References 
0.02-30 Odour threshold [154, 155] 
10 Eye irritation [154] 
50-100 Conjunctiva and respiratory irritation [155] 
100 Olfactory paralysis [156] 
500-700 Loss of consciousness, respiratory paralysis and death in 30-
60 min 
[155] 
700-1000 Rapid unconsciousness, cessation of respiration, 
cardiopulmonary arrest and death 
[155, 157] 
 
1.3.3 Endogenous generation and metabolism of H2
From a toxic pollutant to becoming a novel biological mediator, it all started in 1989 
when the first and most important evidence of endogenous sulfide levels in the brain 
tissues of rat (1.6 µg/g) [
S in mammals 
140] and in normal human postmortem brainstem (0.7 µg/g) 
[138, 140] were reported. Gradually, H2
142
S was also discovered to be produced 
endogenously in the blood [ ] and in the heart [158]. 
 The endogenous production of H2
8-11
S in variety of cells, tissues, organs and 
systems is controlled by two pyridoxal-5’-phosphate (PLP)-dependent enzymes: 
cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) [ ] with L-
cysteine and/or homocysteine as the main substrate [7, 159]. A new PLP-independent 
enzyme, 3-mercaptopyruvate sulfurtransferase (3MST), which uses L-cysteine and α-
ketoglutarate substrates, in combination with cysteine aminotransferase (CAT), has 
24 
 
also been identified as another possible candidate for H2 15S production [ ]. The 
mechanisms for H2
 Although these three enzymes have been detected in variety of tissues, their 
tissue- and cell-specific distributions are quite different. For example, in some tissues, 
both CBS and CSE are needed for H
S production is summarized in Figure 1.2.   
2
160
S generation, whereas in others, one enzyme 
predominates. In 1995, Awata and team found that although CBS and CSE were both 
detected in six different brain regions in rat, the activity of CBS was > 30-fold greater 
than that of CSE [ ]. Through Northern blot analysis later, the transcriptional 
expression of CBS in rat brain (hippocampus, cerebellum, cerebral cortex and 
brainstem) was confirmed but no CSE mRNA was identified [12]. Inhibition of CBS 
resulting in reduced H2S production further substantiated that CBS is the major 
endogenous enzyme for H2 12S production in the brain [ ]. CBS is therefore found to 
be mainly expressed in the hippocampus and cerebellum [12], whereby it is localized 
in astrocytes [161, 162],   whereas CSE is expressed in the cardiovascular system, the 
ileum, portal vein and thoracic aorta [163]. As for 3MST, it is mainly localized to 
neurons and vascular endothelium [164, 165]. With CBS mostly localized in 
astrocytes [161, 162] and 3MST in neurons [164], H2S (free H2S or bound sulfane 
sulfur)  generated by these two enzymes appears to participate in memory, cognition, 
and neuroprotection. On the other hand, H2
166
S generated by CSE in the peripheral 
nervous system may be involved in the autonomic control of the cardiopulmonary and 
gastrointestinal functions [ ].  
 There are two possible mechanisms in which H2S is released from its major 





S as sulfur stores and is released in response to physiologic signal such as neuron 
excitation and other stimulation [ ]. In cells, two forms of sulfur stores have been 
identified [168, 169]. Acid-labile sulfur, mainly localized to iron-sulfur center of 
enzymes in mitochondria, releases H2S under acidic conditions and has been 
generally termed as “brain sulfide” when measured in brains of rats, humans and 
bovines. Another form of storage is known as bound sulfur, whereby it is localized to 
cytoplasm and releases H2 170S in reducing conditions [ ]. However, the general 
consensus supports H2S to be released from bound sulfur store since acid-labile sulfur 
only releases H2 167S at pH 5.4 or less [ ].  
H2
154
S in vivo is oxidized in mitochondria before excreted through urine as free 
or conjugated sulfate [ ]. Although the mechanisms are poorly understood, free 
H2 171S is oxidized to thiosulfate, sulfite and finally sulfate by thiosulfate [ ] or could 
be methylated by thiol-S-methyltransferase enzyme to become methanethiol and 
dimethylsulfide [171]. H2
171
S can also be bound to an oxidized form of haemoglobin 
called “methemoglobin” [ ] although debate has that it is less likely for H2S to be 
transported from the brain to the clearance organs such as lungs, liver and kidneys as 
it is found that H2 172S concentration in the blood is less than 14 nM [ ]. On the other 
hand, in vitro studies showed that H2
173
S decays rapidly and has a short half-life of 
about 10 min [ ]. Interestingly, the beneficial effect of H2
174
S is still seen even after 
washing prior to subjection to oxidative stress-inducing insults [ ]. These imply 
that H2
167
S could be stored and released immediately in response to physiological 
stimulation, and hence triggers cascades of events [ ].  
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Based on various group findings, physiological concentration of endogenous 
H2S measured could vary from as low as nanoMolar (nM) to as high as microMolar 
(µM). Older literature reported that H2 12S in the brain tissue is to be 47-166 µM [ , 
138-140, 163, 175]; plasma: 34-46 µM [142, 176, 177], 274µM [178]; heart: 130 µM 
[170]; lung: 30 µM [147]; liver: 26 µM  [170], 144 µM [175]; and kidney: 40 µM 
[170], 200 µM [175]. However, in 2008, Furne and team reported that the mean free 
hydrogen sulfide concentrations in mouse brain and liver are only 14 ± 9 nM and 17 ± 
8 nM respectively [179]. Consistently, this low level of  free H2
167
S was also reported 
by Ishigami and team using a novel method involving silver particle [ ]. These 
disputes could be due to the evanescent and reactive nature of H2S which makes it 
more impossible to accurately measure its concentration in aqueous solution. 
Henceforth, a more direct, stable and reliable method needs to be developed before a 
more conclusive range of H2
 












































Figure 1.2 Schematic representation of the endogenous H2S biosynthesis. H2S 
can be endogenously produced from L-cysteine by various enzymes. L-cysteine is 
initially derived from homocysteine with CBS catalyzing the β-replacement reaction 
between homocysteine and serine to yield cystathionine, which is then lyzed by CSE 
into L-cysteine and α-ketobutyrate. On one hand, L-cysteine is hydrolyzed by either 
CBS or CSE to produce H2S with pyruvate and ammonia as by-products. On the 
other hand, cysteine reacts with α-ketoglutarate via the catalysis of cysteine 
aminotransferase (CAT) to yield 3-mercaptopyruvate which in turn undergoes 
desulfuration by 3MST to produce H2S and pyruvate. H2S can be stored as bound 
sulfane sulfur in neurons and astrocytes and releases free H2
 




1.3.4 Neuropathology of H2
Several studies have suggested that abnormal generation and metabolism of H
S  
2S may 
provoke the pathogenesis of CNS diseases. For example, disturbed H2
180
S synthesis in 
the brain has been demonstrated in patients with PD [ ], Alzheimer’s disease (AD) 
[181], Down’s syndrome [182] and stroke [183], as summarized in Table 1.3. 
Deficiency of CBS in human results in homocysteinuria, with increased plasma levels 
of homocysteine (Hcy) and methionine but decreased levels of cysteine. Apart from 
ischemic stroke which has independent risk factor of hyperhomocysteinemia [184], 
significant elevated level of Hcy was found in the cerebrospinal fluid of PD and AD 
patients [185].   
 In PD patients treated with L-Dopa, elevated plasma Hcy levels are detected 
[180]. The inability to convert excessive Hcy to cysteine due to CBS biosynthesis 
derangement eventually affected the synthesis of an anti-oxidant, the glutathione 
[186]. Reduced glutathione level was found in postmortem PD nigra [70-72]. As for 
subjects with AD, it was first found that the level of CBS activator, S-
adenosylmethionine (SAM), was severely decreased [187]. This was followed by the 
findings that total Hcy in the brain and serum were increased in AD patients [188]. 
However, in the case of Down syndrome's patients, overproduction of endogenous 
H2 182S was reported [ ]. Urinary thiosulfate (a metabolite of H2
182
S) and erythrocyte 
sulfhemoglobin levels in Down syndrome individuals were comparatively higher than 
diet-matched controls [ , 189]. As for ischemic stroke rat model, it was found that 
middle cerebral artery occlusion caused an increase in the H2
183
S level as well as in its 
synthesizing activity in the cerebral cortex [ ]. Intriguingly, administration of 
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cysteine or sulfide donor, NaHS, significantly increased the infarct volume [190]. 
Seemingly, overproduction or abnormal generation H2
 
S may be involved in the 
pathogenesis of various neurodegenerative diseases.  
Table 1.3 
Neuropathological roles of H2S  
CNS diseases Evidences References 
Parkinson disease (PD) Elevated plasma homocysteine levels [180] 
Reduced glutathione levels [186] 
Alzheimer's disease 
(AD) 
Decrease in S-adenosylmethionine (SAM), a CBS 
activator  
[187] 
Increase in total homocysteine in the brain and serum [188] 
Down's syndrome Overproduction of endogenous H2 [S 182] 
Higher urinary thiosulfate (a metabolite of H2 [S) and 
erythrocyte sulfhemoglobin levels 
182, 189] 
Ischemic stroke Middle cerebral artery occlusion increased H2 [S level 
in the cerebral cortex 
183] 






1.3.5 Neurophysiological roles of H2
Since the first description of endogenously produced H
S 
2S in mammalian tissues, there 
has been exponential growth of scientific interest in H2
 
S as a biological mediator in 
the central nervous system.  
1.3.5.1 H2
H
S as a neuromodulator 
2
The first ever report on the possibility of H
S regulates neuronal activity 
2S as an endogenous neuromodulator 
surfaced in 1996 when Abe and team showed that although  H2S at high 
concentration (≥320 µM) inhibited synaptic transmission, H2
12
S at physiological 
concentration (≤130 µM), selectively enhanced the N -methyl-D-aspartate (NMDA) 
receptor-mediated responses and improves the induction of long-term potentiation 
(LTP) in the hippocampus, a synaptic model of learning and memory [ ]. This LTP 
induction happened only in the presence of a weak tetanic stimulation. The same 
group did further occlusion experiments which showed that the potentiation induced 
by H2S with a weak tetanic stimulation shares common mechanisms with LTP 
induced by a strong tetanic stimulation. These results suggest that H2S facilitates LTP 
not at quiescent, but active synapses and H2S is involved in associative learning. 
Interestingly, in the presence of a NMDA receptor specific blocker, 2-amino-5-
phosphonovalerate, simultaneous application of H2S with a weak tetanic stimulation 
did not induce LTP. These findings strongly suggest to us that the induction of LTP 





S and NMDA receptors interaction may possibly be mediated by the 
activation of cyclic-AMP (cAMP)-dependent protein kinase pathway [ ]. NaHS 
(an H2S donor, 1-100 µM) concentration-dependently increased the production of 
cAMP in primary cultures of rat cerebral, cerebellar neurons, and glial cells. By 
inducing the production of cAMP, H2
191
S increased the sensitivity of NMDA receptor 
expressed in oocytes to bind to its ligand [ ]. It has also been shown that 
phosphorylation of NMDA receptors by activation of cAMP would lead to increased 
Ca2+ 192 permeability [ , 193] and potentiate both early and late phase of LTP [194]. 
All of these data suggest that H2
 
S may modulate NMDA receptors by changing 
intracellular cAMP level which then enhances LTP induction. 
H2S increases intracellular Ca2+ and induces Ca2+
Reciprocal interactions are found between neurons and glia as glia possesses 
neurotransmitter receptors and responds to transmitter released from neurons. Neural 
activity evokes glial calcium waves, and in return, glial calcium waves drive neuronal 
activity. Communication between each glia is carried out by increasing intracellular 
concentration of Ca
 waves in astrocytes   
2+ and propagating the signal as Ca2+ waves. As the Ca2+ waves 
are often appeared to be initiated at the sites of contact with neurons, this suggest that 
glial Ca2+ 192 waves are initiated upon neuronal excitation [ ]. 
In neurons, H2S enhances the NMDA receptor-mediated responses. However, 
H2S alone does not induce the increase in intracellular Ca2+ in neurons. In contrast, 
H2S increases intracellular Ca2+ concentration by mainly increasing Ca2+ influx in 
astrocytes. The induction of Ca2+ waves in astrocytes by H2S was suppressed when 
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voltage-dependent Ca2+ channel blockers such as La3+, Gd3+, and ruthenium red were 
added, suggesting that astrocytes possess H2
Now the question of whether H
S-sensitive molecules or receptors.  
2S has a direct or indirect effect on the Ca2+ 
channel arises. Literature finding has that when the ATP-dependent K+ channel is 
block, the membrane is depolarized and a voltage-dependent Ca2+
195
 channel can be 
activated [ ]. To eliminate this alternative hypothesis, an ATP-dependent K+ 
channel blocker, glibenclamide was added. Result showed that glibenclamide did not 
inhibit NaHS (an H2S donor) response. The same phenomenon was observed with 
tetraethyl ammonium (TEA), a broad spectrum K+ channel blocker, which further 
suggest that H2S activates Ca2+ channels but not ATP-dependent K+ 196 channels [ ].    
Upon neuronal excitation, Ca2+ waves are induced in astrocytes. These waves 
are then propagated to neighbouring astrocytes and synapses to modulate its activity. 
Although neuronal transmission is fast, the propagation of Ca2+ 
193
is slow. The 
involvement of astrocytes may enable time-delayed modification of synaptic 
transmission [ ].  
 
1.3.5.2 H2
The novelty of H
S as a neuroprotectant 
2S has been studied and its protective effect on neurons, microglia, 
astrocytes and animal models are widely reported. Among the protective effects of 
H2
 




Oxidative stress is caused by an overabundance of reactive oxygen species (ROS). 
Oxidative damage to proteins, lipids and nucleic acids has been found in the 
substantia niagra region in the brain of PD patients [44, 197, 198]. Scientific evidence 
has demonstrated that the reduction of anti-oxidant protein glutathione could 
contribute to the pathogenesis of PD [71, 72]. Glutathione, highly distributed in 
astrocytes and oligodendrocytes, acts to protect against endogenously produced ROS 
either directly or by inducing generation of other anti-oxidants [101]. In addition, 
glutathione protects against excitotoxins such as glutamate and cysteine as it could act 
as a non-toxic storage form of cysteine and glutamate [101].  
In a study done by Lu et. al, H2S (100µM) increased glutathione production in 
primary cultured rat cortical astrocytes by enhancing glutamate uptake transporters. 
In this study, H2O2 suppressed glutamate uptake and glutathione production in the 
astrocytes and H2S was able to reverse these effects, thus decreasing ROS production. 
This protective effect was abolished when L-trans-pyrrolidine-2,4-dicarboxylic 
(PDC), a specific glutamate uptake inhibitor, was added, signifying the importance of 
glutamate uptake function in H2S. In another study done by Kimura et. al, it was 
shown that H2
14
S protected primary cultures of neurons from oxidative glutamate 
toxicity via enhancement of γ-glutamylcysteine synthetase activity and up-regulation 
of cysteine transport (Cysteine is the rate-limiting substrate for the synthesis of 
glutathione) [ ]. In short, these findings suggested that H2S could protect against 
oxidative glutamate toxicity in brain and thus H2S could be of therapeutic value 




In PD patients, elevated level of pro-inflammatory factors such as nitric oxide (NO), 
interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) are 
detected in the cerebrospinal fluid and basal ganglia [85, 199].  In 2007, Hu et. al. 
demonstrated that H2S (100-300µM) attenuated lipopolysaccharide (LPS)-induced 
inflammation in microglia by inhibiting p38 mitogen-activated protein kinase 
(MAPK). H2S significantly decreased the NO and TNF-α secretion induced by LPS 
in microglia cells. Western blot analysis showed that H2S attenuated p38 MAPK 
phosphorylation induced by LPS.  Thus, from the result, the author hypothesized that 
H2 143S acted via p38 MAPK pathway [ ]. Similarly, the anti-inflammatory effects of 
H2
200
S were also demonstrated in amyloid-β (Aβ)-induced cell toxicity in BV-2 
microglial cells, an in vitro model of AD [ ].  
 However, it should be note that H2S could be pro- or anti-inflammation 
substance. GYY4137, a slow-releasing H2S donor inhibited LPS-induced release of 
pro-inflammatory mediators and increase the synthesis of IL-10, an anti-inflammatory 
chemokine. In contrast, the rapid release of H2S from NaHS at high concentration 
increased the synthesis of pro-inflammatory factors. Therefore, it can be concluded 
that the rate of generation of H2S plays an important part in determining whether H2
194
S 
is a pro- or anti-inflammatory mediator [ ].  
 
Anti-apoptosis 
Apoptosis is known as a programmed cell death. Although apoptosis is unlikely the 
primary cause for PD, it is hypothesized to become activated in PD through oxidative 
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stress and inflammatory processes. Activation of apoptosis is likely to represent the 
end-stage processes in PD neurodegeneration. Mitochondrial dysfunction is a 
prominent feature in apoptosis [201]. Recently, Hu et. al. reported that H2S 
ameliorated cell-injury induced by rotenone, a toxin commonly used to establish PD 
models, in human neuroblastoma cell line (SH-SY5Y). Hu and co-workers 
demonstrated that apoptosis was inhibited mainly due to the preservation of 
mitochondrial function. H2S (100-300µM) regulateed the mitoKATP
173
 channel and 
hence inhibited the apoptosis cascade such as preventing mitochondrial membrane 
potential (MMP) dissipation, cytochrome c release and caspase-9/3 activation [ ]. 
In another study by Yin et. al., 1-methyl-4-phenylpyridinium ion (MPP+) was used to 
induce PD model in PC12 cells. H2
202
S (400µM) inhibited apoptosis by blocking the 
loss of MMP and overproduction of ROS [ ].   
 
1.3.6 H2
To date, ER stress has been identified as the new potential mediator of PD and several 
other human diseases including AD, stroke, diabetes, cardiac disease and cancer [
S and endoplasmic reticulum (ER) stress 
52, 
53]. Autopsy on the brains of patients with Alzheimer's disease shows 
hyperactivation of the PKR-like ER kinase-eukaryotic initiation factor 2alpha 
(PERK-eIF2α) UPR pathway, indicating  the presence of ER stress activation [49, 
203]. Parkinsonian mimetics, 6-hydroxydopamine (6-OHDA), 1-methyl-4-
phenylpyridinium (MPP+
4
) and rotenone are reported to specifically induce ER stress 
and activate the UPR signaling components, killing dopaminergic neurons [ , 50].  
  Although the effect H2S on PD-induced ER stress is unknown, the 
association between H2S and ER stress has been widely explored especially in the 
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cardiovascular research field. In a hyperhomocysteinemia (HHcy)- induced 
cardiomyocytic ER stress rat model, H2S levels and the H2S-generating enzyme CSE 
activity in the myocardium were significantly reduced. The activities of myocardial 
mitochondrial respiratory enzymes succinate dehydrogenase, cytochrome oxidase and 
manganese superoxide dismutase were dysfunctional in HHcy rats. The 
administration of H2S reversed the homocysteine (Hcy) effect by significantly 
reducing plasma total Hcy and restoring the enzyme activities level, accelerating the 
scavenging of H2O2 and superoxide anion. The expression of an indicator of ER 
stress, glucose-regulated protein 78 (Grp78 or BiP), induced by Hcy in vivo and in 
vitro, was also inhibited by H2 47S treatment [ ]. Apart from Grp78, in 2010, the same 
group proceeded further by reporting that H2S supplementation decreased 
expressions of ER stress-associated proteins, including CHOP and caspase-12 in 
myocardial tissues of HHcy rat model. At the same time, in vitro results showed that 
H2
76
S attenuated Hcy, thapsigargin or tunicamycin-induced CHOP, cleaved caspase-12 
and p-eIF2α expressions in H9c2 cell line [ ]. These data suggests that H2
 A contradicting H
S can 
attenuate cardiomyocytic ER stress in HHcy-induced cardiomyocytic injury.  
2S effect was reported when Yang et al. showed that 
increase in the release of endogenous H2
204
S by transfecting INS-1E cells , an insulin-
secreting beta cell line, with a recombinant defective adenovirus containing the CSE 
gene (Ad-CSE), up-regulated BiP and CHOP, and stimulated apoptosis [ ]. The 
discrepancy of the effect of H2S could lie within the sensitivity of different cell and 
also different concentration of H2
 
S used.  
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1.4 SH-SY5Y cells 
Since PD is a major societal health problem, the development of a stable and reliable 
dopaminergic neuronal cell model is particularly necessary to enable the studying of 
PD pathogenesis and therapeutic strategies. Over the years, SH-SY5Y human 
neuroblastoma cell line has become a well-known cell model for PD research as it is 
easily obtained and possesses many qualities of substantia nigra (SN) neurons. A 
thrice cloned subline of SK-N-SH, SH-SY5Y cell line originated from a bone marrow 
biopsy of a neuroblastoma patient with sympathetic adrenergic ganglial [205]. Since 
then, SH-SY5Y cells have been widely used as model of neurons. The cell line 
expresses tyrosine hydroxylase (TH), dopamine-β-hydroxylase and dopamine 
trasnsporter [206]. With the capability to proliferate in culture for long periods 
without contamination [206], SH-SY5Y cell line is thus suitable for use as an in vitro 
neuronal characteristics model including neuronal metabolism, neuroadaptive 




1.5 Research rational and objectives  
Affecting 2% of the population over the age of 60 [208], PD is a neurological 
disorder resulted from degeneration of dopaminergic neurons in the SN, accompanied 
by an alteration of dopamine concentration in the striatum [1]. Although the etiology 
of PD remains elusive, oxidative stress and generation of ROS from both impaired 
mitochondrial and dopamine metabolism are important mediators of neuronal death in 
PD [19]. Intriguingly, recent studies have also pointed to ER stress as another 
potential mediator responsible for PD pathogenesis [4]. Aggravated by the fact that 
there is no cure for the disease and the present L-Dopa treatment could lead to pro-
oxidant damage in the long-run [19], a new therapy for this second most common 
neurodegenerative disease is therefore, much needed.   
 6-OHDA has been shown to selectively induce oxidative stress [128], ER 
stress [4] and cell injury [129, 130] in dopaminergic neurons. H2
14
S, a novel 
neuromodulator, on the other hand was shown to be capable of suppressing oxidative 
stress by inducing glutathione production [ ] and enhancing glutamate 
transportation [174], preserving mitochondria function by activating KATP
173
 channel 
[ ] and maintaining intracellular homeostasis via elevation of Hsp90 levels [209]. 
Therefore it merits study to investigate whether H2
 The present study aims to determine the in vitro effect of H
S could protect against 6-OHDA-
induced cell injury and ER stress in SH-SY5Y cells.  
2
• The effect of H
S on 6-OHDA or 
more specifically:  




• The effect of H2
The findings from the present work were expected to contribute to the 
biological profile of H
S on 6-OHDA-induced ER stress in SH-SY5Y cells as well 
as its underlying signaling mechanisms.  
2S and its pathophysiological significance in PD. Moreover, 









H2S, an emerging novel neuromodulator, plays various roles in the regulation of 
central nervous system functions. Physically, H2
12
S potentiates N-methyl-D-aspartate 
(NMDA) receptors and improves the induction of long-term potentiation (LTP) in the 
hippocampus, a synaptic model of learning and memory [ ]. In addition, we and 
others have reported that H2S regulates calcium homeostasis in astrocytes and 
microglia, suggesting that H2 98S participates in the regulation of neuronal activity [ ].  
Apart from that, H2
14
S also helps to reduce oxidative stress by inducing the production 
of glutathione, an anti-oxidant, and suppresses oxidative stress in mitochondria [ , 
210].  
 Besides the physiology functions, H2S also plays important roles in the 
pathological processes of neurodegeneration diseases. Our group has recently  
demonstrated that H2S suppresses oxidative stress induced by hydrogen peroxide 
(H2O2
174
) by improving the glutamate transporters activities and thus increases 
glutathione production as well as inhibits lipid oxidation [ ]. We also showed that 
H2
143
S is able to attenuate neuroinflammation induced by lipopolysaccharide (LPS) 
[ ] and amyloid-β (Aβ) [200]. We proceeded to show that H2
173
S is able to protect 
cells against cell injury induced by neurotoxin such as rotenone via preservation of 
mitochondrial function [ ]. Amidst the novelty of H2S, however the effects of H2S 
against 6-OHDA neurotoxin are still unknown. Therefore, the present study is 
designed to investigate the effects of H2S on 6-OHDA-induced cell injury in SH-
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SY5Y cells. The involvement of various protein kinase C (PKC) isoforms and Akt 
signaling pathways were also examined.  
 
2.2 Materials and methods 
 
2.2.1 Chemicals and reagents 
Sodium hydrosulfide (NaHS), 6-OHDA, methyl thiazolyl tetrazolium (MTT) were 
purchased from Sigma-Aldrich (St Louis, MO, USA). Gö6976 (a PKCα
211
 inhibitor) 
[ ], EAVSLKPT (a PKCε 212-selective peptide translocation inhibitor) [ ], rottlerin 
(a PKCδ 213 inhibitor) [ ] and LY294002 (LY) (a phosphoinositol 3’ kinase (PI3K) 
inhibitor) [214] were obtained from Calbiochem (Darmstadt, Germany). All 
chemicals were dissolved in deionized water except Gö6976, rottlerin and LY294002, 
which were dissolved in DMSO at a final concentration not more than 0.05%.  
 Primary antibody of ß-tubulin and PKCε were from Santa Cruz Biotechnology 
while PKCα and PKCδ
 NaHS was used as an H
 as well as polyclonal anti-phospho (p)-Akt rabbit IgG and 
polyclonal anti-total-Akt rabbit IgG were purchased from Cell Signaling Technology. 
Anti-Tyrosine hydroxylase (TH) antibody was obtained from Sigma-Aldrich (St 
Louis, MO, USA).  
2S donor. When H2S is dissolved in water at pH 7.4, 
HS- is released and forms H2S with H+. This provides a solution of H2
137
S at a 




2.2.2 Cell culture 
The human neuroblastoma cell line, SH-SY5Y, obtained from the American Type 
Culture Collection (Manassas, VA), was maintained in Dulbecco’s modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 0.05 U ml-1 
penicillin and 0.05 mg ml-1  streptomycin at 37 ºC in a humidified atmosphere 
containing 5% CO2
 
/95% air. Cultured medium was changed twice a week during cell 
growth.  
2.2.3 Cell treatment 
Cells were plated onto 96-well plates for viability tests or 35 mm dishes and 
incubated overnight as it grew into 80%-90% confluency. Regular medium was 
replaced with low-serum medium (0.5% FBS/DMEM) immediately before treatment. 
Note that for LY294002 (LY) treatment, cells were serum starved for 4-6 h prior to 
treatment. After pretreatment with NaHS for 10 min or 1 h, cells were washed twice 
with PBS solution and incubated in fresh low-serum media with 6-OHDA. Each 
kinase inhibitor was added 30 min before NaHS treatment. Cells were incubated for 
12 h after each exposure to toxins, and cell viability was measured using the MTT 
assay system. 
 
2.2.4 Cell viability assay 
Cell viability was measured using the MTT reduction assay as described previously 
[173]. At the end of each treatment, MTT was added to each well at a final 
concentration of 0.5 mg ml-1  and the cells were further incubated at 37 ºC for 4 h. 
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Then, the insoluble formazan was dissolved with dimethyl sulfoxide (DMSO). 
Colorimetric determination of MTT reduction was measured at 570 nm with a 
reference wavelength at 630 nm.  
 
2.2.5 Cell fractionation for determining PKC isoform translocation 
PKC isoform translocation was detected with the cell fractionation method as 
described previously with modifications [215]. Treated cells were incubated and 
lysed at different time points (1 h, 2 h, 6 h). SH-SY5Y cells were lysed with 200 µl 
ice-cold lysis buffer containing 125 mM NaCl, 25 mM Tris (pH 7.5), 5 mM EDTA, 
1% Nonidet P-40 and protease inhibitors and shaken on ice for 1 h. The cell lysate 
was centrifuged at 500 g at 4 ºC for 10 min to discard the nuclei-rich pellet. The 
supernatant was recentrifuged at 20,000 g at 4 ºC for 20 min. The supernatant was 
collected as cytosolic fraction while the pellet was resuspended in 60 µl cell lysis 
buffer containing 1% Triton X-100 and shaken on ice for another 1 h and then 
centrifuged at 20,000 g at 4 ºC for 20 min. The second supernatant was collected as 
membrane fraction. Epitopes were exposed by boiling the protein samples at 90 ºC 
for 5 min. Western blots were performed to examine the PKC isoforms translocation.  
 
2.2.6 Preparation of cell lysates for the detection of TH and phosphorylated Akt 
A cell lysate technique was adopted from the literature [216, 217]. Cells were washed 
twice with phosphate-buffered saline (PBS) after treatment and lysed with 200 µl ice-
cold lysis buffer containing 125 mM NaCl, 25 mM Tris (pH 7.5), 5 mM EDTA, 1% 
Nonidet P-40, 0.4% deoxycholic acid (additional 10 mM NaF and 1 mM Na3VO4 are 
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added for detection of phosphorylated Akt) and protease inhibitor cocktail tablet 
(Roche Diagnostics, Penzberg, Germany) and shaken on ice for 1 h. After 
centrifugation at 13,000 g at 4 ºC for 15 min, supernatant was collected and denatured 
by SDS-sample buffer. Epitopes were exposed by boiling the protein samples at 100 
ºC for 5 min. 
 
2.2.7 Western blot assays 
Protein concentrations were determined with NanoDrop Spectrophotometer (ND-
1000, NanoDrop technology). Equal amount of protein samples were separated by 
electrophoresis using a 10% sodium dodecyl sulfate-polyacrylamide (SDS/PAGE) gel 
and transferred onto a nitrocellulose membrane (Whatman®, Germany). After 
blocking in 10% milk with TBST buffer (10 mM Tris-HCl, 120 mM NaCl, 0.1% 
Tween-20, pH 7.4) at room temperature for 1 h, the membrane was incubated with 
various primary antibodies at 4 ºC overnight. Membranes were washed three times in 
TBST buffer, followed by incubation with 1:10000 dilutions of horseradish 
peroxidase-conjugated (HRP) anti-rabbit IgG at 25 ºC for 1 h, and washed three times 
in TBST. Visualization was carried out using ECL® (plus/advanced 
chemiluminescence) kit (GE healthcare, UK). The density of the bands on Western 
blots was quantified by Image J software.  
 
2.2.8 Cell transfection and apoptotic detection          
SH-SY5Y cells (1×105) were seeded onto six-well plates and transfected with CBS-
PME185-HA vector (a gift from Dr. Hideo Kimura) or with empty vector alone as a 
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control using lipofectamine 2000 transfection reagent. After transfection for 24 h, 
cells were washed with Krebs solution for twice and then treated with 6-OHDA (50 
µmol L-1
    To visualize nuclear morphology, cells were also stained with 2.5 μg ml
) for 4 h. The apoptosis was examined with an Annexin V FITC detection kit 
(Calbiochem, Cat. No. PF032, Darmstadt, Germany) and analyzed with fluorescence 




DNA dye Hoechst 33342. The nuclei of healthy and viable cells are usually uniformly 
stained, while apoptotic cells would show condensed or fragmented nuclei.  
2.2.9 H2
The procedures are essentially described in the literature with modifications [
S measurement 
218]. In 
brief, aliquots (500 µl) of culture solution (Krebs’ buffer) were mixed with 
trichloroacetic acid [10% (w/v), 250 µl], zinc acetate [1% (w/v), 250 µl], N,N-
dimethyl-p-phenylenediamine sulfate (20 µM, 133 µl) in 7.2 M HCl and FeCl3 (30 
µM, 133 µl) in 1.2 M HCl in parafilm-enveloped Eppendorf tubes. After 15 min, this 
mixture was centrifuged at 4000 g for 10 min. The supernatant was collected and its 
absorbance was measured in 96-well plates at a wavelength of 670 nm. All samples 
were assayed in duplicate and calculated against a calibration curve of NaHS 
dissolved in Krebs’ buffer: 115 mM NaCl, 2.5 mM KCl, 2.46 mM MgSO4, 2 mM 
CaCl2, 5.6 mM glucose, 1.38 mM NaH2PO4, and 25 mM NaHCO3
 
, pH 7.4.  
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2.2.10 Statistical analysis 
All data were presented as mean ± SEM. Statistical significance was assessed with 
one-way analysis of variance (ANOVA) followed by a post hoc (Bonferroni) test for 
multiple group comparison. Differences with p-value less than 0.05 were considered 






Toxicity of 6-OHDA at different concentrations was first examined. As shown in Fig. 
2.1(A), treatment with 6-OHDA (50-200 µM) for 12 h decreased the cell viability of 
SH-SY5Y cells. Pretreatment with NaHS (an H
S protects against 6-OHDA-induced cell injury 
2S donor, 100-1000 µM) for 10 min 
significantly reversed the effect of 50 µM 6-OHDA (Fig. 2.1(B)). These data suggest 
that H2
 
S may protect SH-SY5Y cells against 6-OHDA-induced cell injury. The same 
protective effects were observed when NaHS was given 10 min or 1 h before 









































Fig. 2.1 MTT assay showing the effect of NaHS and/or 6-OHDA on SH-SY5Y 
cell viability. (A) Effect of 6-OHDA on cell viability of SH-SY5Y cells. Cells were 
treated with 6-OHDA at different concentrations for 12 h. (B) Effect of NaHS on cell 
viability in SH-SY5Y cells treated with 6-OHDA. Cells were pretreated with various 
concentrations (10-1000 µM) of NaHS for 10 min before 6-OHDA (50 µM) was 
added for another 12 h. (C) Pretreatment of NaHS for 10 min and 1 h showed similar 
protective effect against 6-OHDA-induced cell injury. Data are presented as mean ± 
SEM, n=5, ***P<0.001 versus control; #P<0.05, ##P<0.01, ###
 




Tyrosine hydroxylase (TH) is an important rate-limiting enzyme in the conversion of 
amino acid tyrosine to dihydroxyphenylalanine (DOPA) for the production of 
dopamine [
S reverses 6-OHDA-induced loss of TH 
133]. In order to confirm the neuroprotective effect of H2S, we first 
examined the effect of H2S (100 µM) on TH protein level. As shown in Fig. 2.2, 
treatment with 6-OHDA for 12 h significantly decreased TH level in SH-SY5Y cells. 
This effect was reversed by H2S, postulating that H2
 
S treatment produces protective 

















Fig. 2.2 Effect of NaHS on TH expression in SH-SY5Y cells treated with 6-
OHDA. Cells were pretreated with NaHS for 10 min before addition of 6-OHDA (50 
µM) for another 12 h. Proteins were extracted and subjected to Western blot analysis 
using the anti-TH and anti-tubulin antibodies. Data are presented as mean ± SEM, 
n=5, ***P<0.001 versus control; ##
 




It has been reported that 6-OHDA-induced cell death is via regulating PKC activity 
[
S regulates translocation of PKC isoforms in 6-OHDA-treated SH-SY5Y 
cells 
19].  In the present study, we examined the effect of 6-OHDA on the translocation of 
PKC isoforms. The time-courses were shown in Fig. 2.3(A). Treatment with 6-
OHDA for 1-6 h inhibited the translocation of PKCα and PKCε from cytosol to 
membrane, but stimulated the activity of PKCδ. The maximum responses were found 
at 2 h for PKCδ, and 6 h for PKCα and ε. NaHS treatment significantly reversed the 
effect of 6-OHDA on the activities of the three PKC isoforms, suggesting that the 
protective effect of H2
 
S may involve different PKC isoforms (Fig. 2.3(B)). 
2.3.4 Effect of NaHS on cell viability in 6-OHDA-treated SH-SY5Y cells in the 
presence and absence of inhibitors of PKC isoforms  
To further confirm the involvement of PKC, we pretreated the cells with rottlerin (5 
µM, a PKCδ inhibitor), Gö6976 (2 µM, a PKCα inhibitor) or EAVSLKPT (200 µM, a 
specific PKCε inhibitor) for 30 min prior to administration of NaHS (100 µM). The 
MTT assay showed that the protective effect of H2S was significantly diminished by 
Gö6976 and EAVSLKPT (Fig. 2.4(A)). However, inhibition of PKCδ with rottlerin 
did not reverse cell injury caused by 6-OHDA (Fig. 2.4(B)). This finding implies that 

























Fig. 2.3 Role of PKC isoforms in the neuroprotective effects of NaHS in SH-
SY5Y cells treated with 6-OHDA. (A-B) a: PKCδ, b: PKCα, c: PKCε. (A) Time 
course for the effect of 6-OHDA on the translocation of PKC isoforms. (B) Effect of 
NaHS (100 µM) on the translocation of PKC isoforms caused by 6-OHDA (50 µM, 2 
h). Right panel shows the effect of various PKC isoform inhibitors on PKC isoform 
translocation. The ratios of membrane/cytosol fraction are normalized to that of 
control group. Data are presented as mean ± SEM, n=5-






Fig. 2.4 The protective effect of NaHS on cell viability in the presence and 
absence of various PKC isoform inhibitors. (A) Blockade of PKCα with Gö6976 (2 
µM, 30 min pretreatment) or PKCε with EAVSLKPT (200 µM, 30 min pretreatment) 
attenuated the protective effect of NaHS (100 µM, 12 h) on 6-OHDA (50 µM, 12 h)-
induced cell injury. (B) Blockade of PKCδ with rottlerin did not reverse cell injury 
caused by 6-OHDA. Data are presented as mean ± SEM, n=5, ***P<0.001 versus 
control; #P<0.05, ###P<0.001 versus 6-OHDA-treated cells; +P<0.05, ++P<0.01 versus 





We also investigated the contribution of PI3K/Akt pathway in the neuroprotective 
effects of NaHS. We first examined the time-course for the effect of 6-OHDA on Akt 
activity. As shown in Fig. 2.5(A), 6-OHDA significantly suppressed Akt activity after 
treatment for 6 h. Fig. 2.5(B) shows the time-course for the effect of NaHS on Akt 
activity. There were two peaks (20-40 min & 4-12 h) for NaHS-induced Akt 
activation.  Bearing the above data in mind, we examined the effect of NaHS on Akt 
activity in cells treated with 6-OHDA for 6 h and 12 h. As shown in Fig. 2.5(C), 
treatment with NaHS reversed the inhibitory effect of 6-OHDA on Akt activity at 
both time points.  
S-induced neuroprotection involves PI3K/Akt activation 
     The involvement of PI3K/Akt pathway was further confirmed with cell 
viability data using MTT assay. As shown in Fig. 2.6, pretreatment with LY294002 (a 
PI3K inhibitor) for 30 min, which alone had no significant effect, markedly reversed 
the protective effects of NaHS on cell viability. Taken together, these data clearly 
suggest that the protective effect of NaHS is via stimulating PI3K/Akt pathway. 
 
2.3.6 Correlation between PKC and Akt 
We further examined whether PI3K/Akt is downstream to PKC activation. As shown 
in Fig. 2.7, the effect of NaHS on Akt activity was abolished by pretreatment of the 
cells with Gö6976 (2 µM, an inhibitor of PKCα) or EAVSLKPT (200 µM, an 





Fig. 2.5 Involvement of PI3K/Akt pathway in the neuroprotective effects of 
NaHS. (A-B) Time-courses for the effect of 6-OHDA (50 µM, A) and NaHS (100 
µM, B) on Akt activity. (C) NaHS reversed the inhibitory effect of 6-OHDA (6 h and 
12 h) on Akt phosphorylation. The histograms represent the ratio of phosphorylated 
protein over total Akt. Data are presented as mean ± SEM, n=5, *P<0.05, ***P<0.001 





Fig. 2.6 Effect of PI3K inhibitor on the NaHS neuroprotection against 6-OHDA-
induced cell injury. Blockade of PI3K with LY294002 (20 µM, 30 min pretreatment) 
abolished the protective effect of NaHS (100 µM, 12 h) on 6-OHDA (50 µM, 12 h)-
induced cell injury.  Data are presented as mean ± SEM, n=5, ***P<0.001 versus 
control; ##P<0.01 versus 6-OHDA-treated cells; +++
 









































Fig. 2.7 Effect of NaHS on Akt activation was dependent on PKC activity. 
Blockade of PKCα with Gö6976 (2 µM, A) or PKCε with EAVSLKPT (200 µM, B) 
attenuated NaHS-up-regulated Akt phosphorylation in SH-SY5Y cells treated with 6-
OHDA for 6 h. Whole cell lysates were prepared for Western blot analysis of total 
Akt and phosphorylated Akt level. The histograms represent the ratio of 
phosphorylated protein over total Akt. Results shown are the mean ± SEM, 
n=5, **P<0.01 versus control; ###P<0.001 versus 6-OHDA-treated 
cells; ++P<0.01, +++P<0.001 versus NaHS + 6-OHDA-treated cells. 
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2.3.7 CBS overexpression attenuates 6-OHDA-induced apoptosis in SH-SY5Y 
cells 
To confirm the role of endogenous H2S, SH-SY5Y cells were transfected with the 
cDNA of CBS, the main enzyme to produce H2S in these cells. As shown in Fig. 
2.8(A), CBS protein expression in SH-SY5Y cells was obviously increased 24 h after 
transfection. Accordingly, H2S concentration in CBS-overexpressed cellular culture 
medium was significantly elevated compared with empty vector–transfected group 
(Fig. 2.8(B)). The H2S level increased to 13.13±1.33 µM at 24 h after CBS 
transfection compared with that in the control group (9.93±0.23 µM). After 
application of NaHS (100 µM) for 10 min, H2S level was 42.73±1.92 µM in medium. 
Thus, the elevated H2
Phosphatidylserine (PS) is located on the cytoplasmic surface of the cell 
membrane during normal condition. Early apoptosis leads to exposure of PS on the 
cell surface. The extracellular PS therefore binds with Annexin V-FITC. Late 
apoptotic cells not only bind with Annexin V-FITC but can also be stained with 
propidium iodide. As shown in Fig. 8C, 6-OHDA increased the number of cells with 
green (AnnexinV stained by FITC) and red (stained by propidium iodide) 
fluorescence in the vehicle group (empty vector-transfected cells). This effect was 
significantly attenuated by the overexpression of CBS.  
S level caused by over-expression of CBS is much lower than 
that caused by exogenous application of NaHS. 
     The beneficial effects of endogenous H2S against 6-OHDA-induced apoptosis 
were also confirmed by Hoechst 33342 staining assay. Representative 
photomicrographs of nuclei morphology of SH-SY5Y cells were shown in the right 
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panel of Fig. 2.8(C). The effect of 6-OHDA led to the condensation and 
fragmentation of nuclei (a characteristic of apoptosis). CBS overexpression 
significantly attenuated this effect. Taken together, these data suggest that 6-OHDA-
induced cell apoptosis was attenuated by endogenous H2
 



















Fig. 2.8 Effect of endogenous H2S on 6-OHDA-induced cell apoptosis in SH-
SY5Y cells. (A) Transfection of CBS cDNA into SH-SY5Y cells increased the 
protein expression of CBS. (B) Effect of CBS overexpression and exogenous 
application of NaHS on endogenous H2S level. Mean ± SEM, 
n=8, *P<0.05, ***P<0.001 versus GFP; ###
 
P<0.001 versus CBS. (C) CBS 
overexpression alleviated 6-OHDA-induced apoptosis. Green: early apoptosis 
indicated by FITC fluorescence; Red: late phase apoptosis stained by propidium 
iodide; Blue: nuclei stained by Hoechst 33342. Photos were taken at X20 







The cornerstone of signs and symptoms of PD are the loss of dopaminergic neurons 
and subsequent dopamine deficit in the brain [1, 19, 219, 220]. Dopamine loss in PD 
is unable to be replaced directly by dopamine replacement therapy as this monoamine 
does not cross the brain capillary endothelial wall, which forms the blood brain-
barrier (BBB). However, the precursor to dopamine, dihydroxyphenylalanine 
(DOPA), is able to cross the BBB owing to the transport via the BBB large neutral 
amino acid transporter. DOPA is then decarboxylated to dopamine by aromatic amino 
acid decarboxylase (AAAD). The rate-limiting step in cerebral production of 
dopamine is the conversion of tyrosine to DOPA via tyrosine hydroxylase (TH) [133]. 
Therefore, at the present, levodopa (L-dopa) is widely used as a treatment to restore 
dopamine concentration in PD patients. However, studies have shown that long term 
usage of L-dopa leads to pro-oxidant damage [19]. Henceforth new therapy is in need. 
In the present study, we provide evidence that H2
221
S, which can easily penetrates 
biological membrane [ ], is able to protect against 6-OHDA-induced cell injury. 
Apart from that, H2S significantly increased the level of TH, the rate-limiting enzyme 
in dopamine production. Our in vitro finding may suggest that H2
     We also examined the protective effect of endogenous H
S may protect 
dopaminergic neurons against 6-OHDA-induced injury.  
2S on 6-OHDA-
induced cell damage. We found that overexpression of CBS only moderately 
increased H2S level, whereas exogenous application of NaHS markedly elevated H2S 
level. However, CBS overexpression still produced obvious protective effects against 
cell apoptosis. This is probably because overexpression of CBS may increase H2S 
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level stably and persistently, whereas exogenous application of NaHS causes a 
transient increase in H2 173S level in the buffer [ ]. This finding reveals that 
endogenously produced H2
210
S is important to protect brain against oxidative stress-
induced neurodegenerative diseases. Our observation is consistent with Kimura’s 
finding that transfection with 3MST also show significant resistant to oxidative stress 
in Neuro2a cells [ ]. 
     We further investigated the possible signaling mechanisms underlying the 
protective effect of H2
19
S on 6-OHDA-induced cell injury. We focused on PKC and 
Akt, because both of them are well-known pro-survival protein kinases and are hence 
thought to be involved in anti-oxidation to promote neuronal protection [ , 222].  
     PKC is a family of well-studied serine-threonine kinases. It is involved in 
many cell functions including cell proliferation, differentiation, apoptosis and gene 
expression. The hallmark for PKC activation is a process called translocation, 
whereby PKC isoforms translocate from the cytosol to subcellular membrane regions 
[215, 223]. The PKC family consists of at least 12 isoforms, among which PKCδ, α, 
and ε 211 are expressed in SH-SY5Y neuroblastoma cells [ , 215, 223]. Various studies 
have shown that different isoforms play different roles in cell functions. PKCα and 
PKCε 224 have been associated with cell proliferation [ , 225], while PKCδ
213
 activation 
contributes to apoptosis [ , 226, 227]. Weinreb et  al.  (2004) reported that PKCα 
phosphorylates Bcl-2 in a site which increases its anti-apoptotic function, while 
overexpression of PKCε
228-230
 elevates the expression of Bcl-2 which inhibits apoptosis 
[ ] . In view of this, we examined the effect of NaHS on translocation of these 
isoforms in SH-SY5Y cells treated with 6-OHDA. We found that 6-OHDA 
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transiently (~2 h) stimulated translocation of PKCδ and sustainably (>6 h) inhibited 
the activities of PKCα and PKCε. These effects were inhibited by NaHS. Blockade of 
PKCα and  PKCε with their inhibitors abolished the neuroprotection caused by H2S. 
However, inhibition of PKCδ with rottlerin did not reverse the cell injury caused by 
6-OHDA in SH-SY5Y cells. These findings suggest that the toxic effect of 6-OHDA 
may predominantly originate from sustained inhibition (>6h) of PKCα and PKCε, but 
not from the transient (~2h) activation of PKCδ. In a similar way, the neuroprotection 
offered by NaHS may mainly result from stimulation of PKCα and PKCε, instead of 
inhibition of PKCδ
     Akt, also known as protein kinase B (PKB), is a key molecule in growth factor 
signaling pathways mediating neuronal survival in both development and disease in 
multiple paradigms including resistance against oxidative insults in the brain [
.  
231]. 
Stimulation of the PI3K pathway is necessary for Akt activation in most instances 
[232]. Once activated, Akt, in turn, inactivates several pro-apoptotic proteins 
including BAD and caspase-9 [233] and therefore promotes cell survival. In the 
present study, we found that blockade of PI3K with its selective inhibitor, LY294002, 
abolished the protective effects of NaHS on cell viability. More importantly, NaHS 
reversed the down-regulated Akt activity caused by 6-OHDA. Our data clearly 
suggest that the protective effect of NaHS on 6-OHDA-induced cell injury is 
mediated by stimulation of PI3K/Akt pathway.   
     Physical interaction between PKC and Akt in human vascular endothelial cells 
results in induction of Bcl-2 and enhancement of protection against apoptotic cell 
death via caspase-3 cleavage inhibition [234]. The activation sequence between PKC 
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and PI3K/Akt has been reported discrepantly in several papers. It has been reported 
that activation of PI3K/Akt controls PKC activity [235]. However, up-regulated Akt 
activity was also observed when PKCα
231
 was overexpressed in 32D myeloid progenitor 
cells [ , 232]. In the present study, we found that inhibition of PKCα and PKCε 
isoforms down-regulated Akt expression level which led to increase cell apoptosis. 
Our findings suggested that Akt could be the downstream effector of PKCα and PKCε
     The results in the present study suggest that the neuroprotection offered by 
H
.  
2S is a pre-conditioning like effect. Our previous study shows that H2
173
S quickly 
decays to undetectable level within 30 min after addition of NaHS into cell culture 
buffer [ ].   This suggests that H2S rapidly stimulates PKC/PI3K/Akt pathway and 
triggers a serious of persistent intracellular responses and therefore protect the cells. 
This preconditioning effect is similar to the mechanisms for the cardioprotection 
conferred by H2 97S preconditioning [ , 215, 236-238].  Our time-course study shows 
that the preconditioning period of NaHS lasts for at least 1 h. At this time point, H2
173
S 
level has already decayed to undetectable level [ ]. This finding excludes the 
possibility that the neuroprotection of H2
239
S is caused by direct inhibition of 
extracellular auto-oxidation of 6-OHDA, another important mechanism for 6-OHDA-
induced dopaminergic cell death [ , 240].  
    In summary, the present observations identify the potentiality of H2S in 
protecting SH-SY5Y cells against 6-OHDA-induced cell injury. The neuroprotective 





S PROTECTS AGAINST 6-OHDA-INDUCED 
ENDOPLASMIC RETICULUM (ER) STRESS 
3.1 Introduction 
Endoplasmic reticulum (ER) stress has been identified as a potential PD mediator [4, 
21, 22]. The association between H2S and ER stress in neurodegeneration disorders 
are not known yet although recent studies have suggested possible roles of H2S in 
modulating ER stress-induced cardiovascular diseases. In rat model of 
hyperhomocysteinemia (HHcy)-induced cardiomyocytic ER stress injury and 
homocysteine (Hcy)-treated H9c2 cells (rat embryonic heart-derived cell line), H2
76
S 
supplementation was shown to antagonize cell injury and suppress the expression of 
various ER stress associated proteins, including glucose-regulated protein 78 (GRP78 
also known as BiP), C/EBP homologous protein (CHOP), cleaved caspase 12, and 
phosphorylation of eukaryotic initiation factor 2alpha (p-eIF2α) [ ]. In another study 
on stress-related ulceration in rats, H2
241
S exposure was also shown to reverse the up-
regulation of ER stress markers [ ]. However, a different effect of H2S was 
reported in INS-1E cells (insulin-secreting beta cell line). Increase in the release of 
endogenous H2 204S not only aggravated stress but also stimulated apoptosis [ ].  
With the disparate roles of H2S in different ER stress-induced experimental 
disease models, we sought to examine the effect of H2S on ER stress associated 
neurodegenerative disease, namely PD. In this study, our group demonstrated for the 
first time the effects of H2S on 6-hydroxydopamine (6-OHDA)-induced ER stress in 
SH-SY5Y cells. The involvement of various pathways such as protein kinase B (PKB 
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or also known as Akt), extracellular signal-regulated kinase 1/2 (ERK 1/2) and heat 
shock protein 90 (Hsp90) were also determined.  
 
3.2 Materials and methods 
 
3.2.1 Chemicals and reagents 
Sodium hydrosulfide (NaHS) was used as an H2S donor. When dissolved in water at 
pH 7.4, HS- is released and associates with H+ to form H2S. This provides a solution 
of H2
137
S at a concentration that is approximately 33% of the original concentration of 
NaHS [ ].  
 NaHS, 6-hydroxydopamine (6-OHDA), methyl thiazolyl tetrazolium (MTT) 
were purchased from Sigma-Aldrich (St Louis, MO, USA). PD98059 (a MEK 
inhibitor), Akt inhibitor (Akti, an Akt inhibitor) were obtained from Calbiochem (San 
Diego, CA, USA). Geldanamycin was obtained from A.G. Scientific, Inc. (San Diego, 
CA, USA). All chemicals were dissolved in deionized water except PD98059, Akti 
 Primary antibodies for detecting poly (ADP-ribose) polymerase (PARP),  
phospho- and total-eIF2α, phospho- and total-Akt, were from Cell Signaling 
Technology while Hsp90 and CHOP/GADD153 were purchased from Santa Cruz 
Biotechnology. Antibody for β-actin was obtained from Sigma Aldrich (St Louis, MO, 
USA).  
and Geldanamycin which were dissolved in DMSO at a final concentration not more 




3.2.2 Cell culture 
SH-SY5Y human neuroblastoma cell line was obtained from the American Type 
Culture Collection (Manassas, VA, USA). It possesses many qualities of substantia 
nigra neurons which made it suitable to be used as neuronal characteristics model 
such as neuronal apoptosis, neurotransmission and neurodegeneration.  
 Cells were maintained in Dulbecco’s modified Eagle’s Medium (Sigma-
Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS) and 
1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA), at 37ºC in a humidified 
incubator (5% CO2
 
/95% air). Cells were passaged twice a week.  
3.2.3 Cell treatment 
Upon reaching 80% confluency, cells were seeded onto 96-well plates or 35-mm 
diameter dishes and incubated overnight. Take note that for cell viability assay, 
regular culture medium was replaced with low-serum medium (0.5% FBS/DMEM) 
immediately before treatment. As for assays on ER stress markers, it is important to 
change the medium in the dishes with a fresh one just before the start of experiments 
as ER stress could be induced by nutrient depletion such as glucose deprivation and 
amino-acid starvation.  
 To study the effect of H2
  
S on cell, NaHS at 100 µM was added to the cell 
medium 10 min before the administration of 50 µM of 6-OHDA. Each inhibitor was 
added 30 min prior to NaHS treatment. Cells were incubated for another 6 h or 12 h 
(for cell viability tests) after each exposure to toxins. 
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3.2.4 Cell viability assay 
Cell viability was assessed by MTT reduction assay as described previously [173]. At 
the end of treatment, cells were incubated at 37ºC with MTT at a final concentration 
of 0.5 mg/mL for 4 h. Purple formazan formed was solubilized with 150 µl dimethyl 
sulfoxide (DMSO). The absorbance of the coloured solution was measured at 570 nm 
with a reference wavelength at 630 nm using a 96-well microplate reader (Tecan 
Systems Inc. USA).    
 
3.2.5 Western blot assays 
Treated cells were washed twice with ice-cold phosphate-buffered saline (PBS) and 
lysed with 100 µL chilled lysis buffer containing 125 mM NaCl, 25 mM Tris (pH 7.5), 
5 mM EDTA, 1% Nonidet P-40, 0.4% deoxycholic acid, 10 mM NaF, 1 mM Na3VO4, 
as well as protease and phosphatase inhibitor cocktails. Cells lysate collected were 
shaken on ice for an hour before subjecting to centrifugation at 13000g at 4°C for 15 
min. Supernatant was collected and denatured by SDS-sample buffer. Epitopes were 
exposed by boiling the protein samples at 100°C for 5 min. Protein concentrations 
were determined with NanoDrop Spectrophotometer (ND-1000, NanoDrop 
Technology). Equal amounts of protein extracts were separated by gel electrophoresis 
using 10% sodium dodecyl sulfate-polyacrylamide (SDS/PAGE) gel and transferred 
to nitrocellulose membranes (Whatman ®, Germany) using a Mini-trans-Blot cell 
(Bio-Rad, Hercules, CA, USA). Membranes were blocked at room temperature for an 
hour in 10% non-fat milk with tris-buffered saline Tween-20 (TBST) buffer. 
Membranes were then incubated with various primary antibodies at 4°C overnight. 
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Membranes were washed three times in TBST buffer, followed by incubation with 
1:10000 dilutions of horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse 
IgG at room temperature for 1 h, and washed for another three times in TBST buffer. 
Visualization was carried out using SuperSignal® West Pico solutions (Thermo 
Scientific, Rockford, IL, USA) and ECL® (advanced chemiluminescence) kit (GE 
Healthcare, UK). The density of the bands on Western blots was quantified by Image 
J software. The relative phosphorylation was normalized to total protein.     
 
3.2.6 Reverse transcription-PCR 
The mRNA levels of BiP, Hsp90 and β-Actin were determined by two-step reverse 
transcription PCR. In brief, total RNA was extracted using TRIzol® reagent 
(Invitrogen, Carlsbad, CA, USA). Homogenized samples were then incubated at room 
temperature for 5 min. Chloroform was added and tubes were shaked vigorously by 
hand for 15 min followed by incubation for 3 min at room temperature once more. 
Samples were centrifuged at 12000g for 15 min at 4°C. Colourless upper aqueous 
phase was transferred to a new tube containing isopropanol and incubated for 10 min 
at 25°C followed by centrifugation at 12000g for 10 min at 4°C. Supernatant was 
thrown away and RNA pellet was washed with 70% ethanol. Samples were vortex 
and centrifuged at 7500g for 5 min at 4°C.  RNA pellets were briefly dried for 10 min 
and dissolved in RNase-free water before subjecting it to 10 min incubation at 60°C. 
RNA concentration was determined with NanoDrop Spectrophotometer (ND-1000, 
NanoDrop Technology). Equal amounts of RNA samples obtained were reverse 
transcribed into cDNA using iScriptTM cDNA synthesis kit (Bio-Rad). Reverse 
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transcription was performed at 25°C (for 5 min), 42°C (for 30 min) and 85°C (for 5 
min). The resulting cDNAs were PCR-amplified using Taq DNA polymerase kit (i-
DNA Biotechnology). PCR primer sequences were summarized in Table 3.1 and 
conditions used for each primers were as such: BiP at 95°C (for 30 sec), 50°C (for 1 
min), and 72°C (for 45 sec) for 24 cycles [4]; Hsp90 at 94°C (for 45 s), 58°C (for 30 
s), and 72°C (for 30 sec) for 30 cycles [242]; β-actin at 95°C (for 30 sec), 55°C (for 1 
min), and 72°C (for 45 sec) for 22 cycles [243]. PCR products were separated on a 
1% agarose gel and stained with ethidium bromide. The optical densities of the 
mRNA bands were analyzed with GelDoc-It Imaging Sytems. The ratio of optical 
density of BiP or Hsp90 mRNA to β-Actin mRNA was the relative amount of BiP or 
Hsp90 mRNA. 
 
3.2.7 Statistical analysis 
All data are presented as mean ± SEM. Statistical significance was assessed with one-
way analysis of variance (ANOVA) followed by a post hoc (Bonferroni)test for 




















Forward: 5’-GACCATGGAGAAAGCTGTAGAGGAA-3’ 2037-2061 371 50 [4] 
Reverse: 5’-CCAAGACACGTGAGCAACTGCTA-3’ 2385-2407 
Hsp90 NM_0010
17963.2 
Forward: 5’-GCTTATTTGGTTGCTGAGAAAGTAACT-3’ 787-812 130 58 [242] 
Reverse: 5’-TTCCACGACCCATAGGTTCAC-3’ 896-916 
β-Actin NM_0011
01.3 
Forward: 5’-AAGAGAGGCATCCTCACCCT-3’ 265-284 218 55 [243] 






6-OHDA is a widely used endogenous neurotoxin in establishing animal model for 
Parkinson’s disease and MTT assay was used to determined cell viability. SH-SY5Y 
cells were treated with 6-OHDA for 12 h in the presence or absence of NaHS, an H
S protects SH-SY5Y cells against 6-OHDA-induced cell death 
2S 
donor. Fig. 3.1(A) shows that 50 µM of 6-OHDA significantly reduced cell viability 
to 48.37%. Pretreatment with NaHS (100 µM, 10 min), which alone had no obvious 
effect, significantly reversed the effect of 6-OHDA and increased the cell viability to 
67.87%. These data suggest that H2
130
S may protect SH-SY5Y cells against 6-OHDA 
induced cell cytotoxicity and these results were comparable to our previous findings 
[ ].  
 Poly (ADP-ribose) polymerase (PARP) is a protein involved in DNA repair 
and apoptosis. Cleavage of full-length PARP (116 kDa) into an 89 kDa fragment is a 
hallmark of cell death.  In the present study, we measured PARP cleavage using 
Western blot analysis to further examine the effect of H2S on 6-OHDA-induced cell 
death in SH-SY5Y cells. As shown in Fig. 3.1(B), treatment of cells with 6-OHDA 
resulted in significant increased in the level of cleaved PARP while pretreatment with 





Fig. 3.1 Effects of NaHS on 6-OHDA-induced cell injury in SH-SY5Y cells. (A) 
Pre-treatment with NaHS (100 µM) for 10 min significantly increased cell viability in 
cells treated with 6-OHDA (50 µM) for another 12 h. (B) Western blot analysis 
showed that NaHS decreased the amount of cleaved PARP. Data were expressed by 
the ratio of cleaved PARP (89 kDa) over β-actin (43 kDa) which was used as control. 
Data are presented as mean ± SEM, n = 5-8, ***P < 0.001 versus control; ## P < 




Studies have demonstrated that ER stress contributes to neuronal death [
S decreases p-eIF2α expression induced by 6-OHDA 
50, 53, 88, 
100]. We first sought to investigate whether 6-OHDA activates phosphorylation of 
eukaryotic initiation factor 2alpha (p-eIF2α) to induce ER stress in SH-SY5Y cells. A 
time-course Western blot analysis showed that 50 µM of 6-OHDA significantly 
increased p-eIF2α expression throughout the period of 1-9 h (Fig. 3.2(A)). 
Pretreatment with 100 µM of NaHS for 10 min before administration of 6-OHDA for 
6 h clearly decreased p-eIF2α expressions, while NaHS alone failed to affect SH-







                              
 
                 
Fig. 3.2 Western blot analysis shows the effects of 6-OHDA and/or NaHS on p-
eIF2α protein expression. p-eIF2α (38kDa) expression was compared by measuring 
gray intensity and area of bands with eIF2α (38kDa). (A) Time course studies 
showing the effects of 6-OHDA on p-eIF2α protein expression. (B) NaHS reversed 
the effect of 6-OHDA (6 h and 9 h) on eIF2α phosphorylation. The histograms 
represent the ratio of phosphorylated eIF2α over total eIF2α. Data are presented as 





To further ascertain that exposure to 6-OHDA induces ER stress, we proceeded to 
monitor the glucose-regulated protein 78 (GRP78 or known as BiP) mRNA level in 
SH-SY5Y cells using RT-PCR. BiP is an ER-chaperone protein whose expression 
level is increased during ER stress [
S decreases BiP mRNA expression induced by 6-OHDA 
244]. As shown in Fig. 3.3(A), 6-OHDA 
treatment led to a significant elevation in BiP mRNA expression at 6-9 h. NaHS alone 
at different time periods had no effect on the BiP mRNA expression levels (Fig. 
3.3(B)). However, 6-OHDA-induced BiP mRNA up-regulation was reversed by 
NaHS treatment at 6 h (Fig 3.3(C)). 6 h was chosen as it was the shortest time point 









Fig. 3.3 RT-PCR shows the effects of 6-OHDA and/or NaHS on the BiP mRNA 
level. (A-B) Time course studies showing that 6-OHDA increased BiP mRNA level 
time-dependently (A), while NaHS alone did not produce significant effect (B). (C) 
Pre-treatment with NaHS significantly reversed the effect of 6-OHDA on BiP mRNA 
level. The histogram shows relative BiP mRNA level compared with β-actin. Data are 





When primary insult is excessive, cell death is initiated [
S decreases CHOP expression induced by 6-OHDA 
52, 53, 57, 102]. C/EBP 
homologous protein (CHOP) participates in ER stress-induced apoptosis [245]. As 
shown in Fig. 3.4(A), 6-OHDA significantly induced CHOP expressions at 6 h and 9 
h. Pretreatment with NaHS for 10 min, which alone had little effect, effectively 
suppressed the CHOP expression induced by 6-OHDA (Fig. 3.4(B)). These data 
suggest that H2
 
S treatment produces protective effect against ER stress-induced 
apoptosis.  
3.3.5 Akt activity, but not ERK1/2, mediates the protective effect of H2S on 6-
OHDA-induced ER stress in SH-SY5Y cells 
Activation of ERK1/2 and Akt pathways are known to play important roles in 
resisting ER stress-induced apoptosis signaling [246]. To determine the involvement 
of Akt and ERK1/2 pathways in H2S neuroprotection against ER stress, we pretreated 
the SH-SY5Y cells with PD98059 (10 µM, a specific ERK1/2 MAPK inhibitor) and 
Akt inhibitor (5 µM, a selective Akt inhibitor) 30 min prior to administration of 
NaHS (100 µM). RT-PCR data showed that Akt inhibitor, but not PD98059, 
significantly reversed the BiP mRNA expression level suppressed by NaHS (Fig. 
3.5(A)). Neither Akt inhibitor nor PD98059 alone had effect on the mRNA 
expression level of BiP. Similarly, administration of Akt inhibitor abolished H2S 
down-regulated p-eIF2α, while PD98059 had no significant effect (Fig. 3.5(B)). 
Taken together, these data clearly suggest that the protective effect of NaHS in 





Fig. 3.4 Effect of  6-OHDA on the CHOP protein expression in the presence or 
absence of NaHS. (A) Time course study for the effect of 6-OHDA on CHOP 
induction. (B) NaHS ameliorated the expression of CHOP. CHOP (29kDa) 
expression was measured by comparing gray intensity and area of bands with β-actin 
(43 kDa). Data are presented as mean ± SEM, n = 3-8, **P < 0.01, ***P < 0.001 versus 
control; ### 
 




Fig. 3.5 The neuroprotective effect of NaHS involves Akt but not ERK 1/2 
pathway. PD98059 (ERK 1/2 inhibitor, 10 µM) and Akti, (Akt inhibitor, 5 µM) were 
given 30 min before addition of NaHS which was applied 10 min before subjecting to 
6-OHDA (50 µM, 6 h). Akti, but not PD98059, abolished the effect of NaHS on BiP 
mRNA level (A) and phosphorylation of eIF2α (B). The histogram shows relative BiP 
mRNA level compared with β-actin and p-eIF2α compared with eIF2α respectively. 
Data are presented as mean ± SEM, n = 6-8, **P < 0.01, ***P < 0.001 versus 
control; # P < 0.05, ## P < 0.01, ### P < 0.001 versus 6-OHDA-treated cells; † P <0.05 
versus NaHS + 6-OHDA-treated cells. 
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3.3.6 Hsp90 mediates the protective effects of H2
Heat shock protein 90 (Hsp90), a molecular chaperone, plays a unique role in cellular 
homeostasis, assisting protein degradation, folding, maturation and preventing 
apoptosis [
S on 6-OHDA-induced ER 
stress in SH-SY5Y cells 
82, 247]. We showed that inhibition of Hsp90 with Geldanamycin (GA, 10 
µM) markedly  induced the up-regulation of ER stress marker, BiP mRNA expression 
level at 3-9 h (Fig. 3.6(A)). Western blot analysis revealed that NaHS treatment alone 
at 6-9 h significantly up-regulated Hsp90 protein expression (Fig. 3.6(B)). 
Pretreatment of NaHS failed to reduce the up-regulated GA-induced BiP mRNA 
expression level (Fig. 3.6(C)), suggesting that Hsp90 may mediate the 
neuroprotective effect of H2
 






    
Fig. 3.6 Effect of Geldanamycin and/or NaHS on BiP mRNA expression or 
Hsp90 protein expression in SH-SY5Y cells. (A) A time course study showing the 
effect of Geldanamycin (an Hsp90 inhibitor, 10 µM), on BiP mRNA level. (B) A time 
course study of the effect of NaHS on Hsp90 protein expression. (C) With the 
blockade of Hsp90, NaHS failed to inhibit the elevation of Geldanamycin-induced ER 
stress marker, BiP mRNA. The histograms represent the ratio of BiP or Hsp90 over 
β-actin. Data are presented as mean ± SEM, n = 4-6, *P < 0.05, ***P < 0.001 versus 
control; #P < 0.001 versus 6-OHDA-treated cells. 
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3.3.7 Interaction between Akt kinase and Hsp90 molecular chaperone  
To evade apoptosis and to promote cell survival, Hsp90 is reported to interact with 
phosphorylated serine/threonine kinase Akt, a protein that promotes survival signal 
[248, 249]. To examine the signaling cascade, we detected Hsp90 protein expression 
in the presence or absence of Akt inhibitor. Interestingly, inhibition of Akt activity 
down-regulated the protein expression level of Hsp90 (Fig. 3.7). These data suggest 
that activation of Akt is necessary for the stimulatory effect of H2
 
S on Hsp90 protein 
expression.   
Fig. 3.7 Blockade of Akt with Akt inhibitor (Akti) attenuated the effect of NaHS 
on Hsp90 expression. Cells were pre-treated with Akti for 30 min before addition of 
NaHS for another 6 h. Proteins were extracted and subjected to Western blot analysis 
using the anti-Hsp90 and β-actin antibodies. Data are presented as mean ± SEM, n = 
6-8, *P < 0.05 versus control; ## P < 0.01 versus 6-OHDA-treated cells. 
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3.4 Discussion  
Hydrogen sulfide is an emerging novel neuromodulator. However, its role in 
neuronal-induced ER stress was unknown although it has been reported to protect 
against ER stress-induced cardiovascular disease [47, 76] and gastric ulceration [241]. 
Therefore, the present study was designed to investigate whether H2
6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin 
widely used for over 30 years in experimental models of PD [
S plays a 
profound role in regulating 6-OHDA-induced neuronal ER stress cell death.  
4, 127, 132, 250]. 
Moreover, as this neurotoxin has similar molecular structure to that of dopamine, it 
shows high affinity for the dopamine transporter and selectively kills dopaminergic 
neurons [128]. Although the underlying cellular and molecular mechanisms in 6-
OHDA-induced neuronal loss remains unclear, ER stress and activation of the UPR 
signaling components have been reported to participate in the killing of dopaminergic 
neurons [4, 50].   
 We first demonstrated that 6-OHDA induced cell death and ER stress is one 
of the major causation of this neuronal death. 6-OHDA induced up-regulation of ER 
stress indicated by ER stress markers such as p-eIF2α, BiP and CHOP. 
Phosphorylation of eIF2α blocks the initiation of gene expression at the translational 
level as to reduce protein load on the ER [251]. BiP is an ER-molecular chaperon 
protein whose expression is increased during ER stress [244]. CHOP is a 29kDa 
protein which participates in ER stress-induced apoptosis [245]. It is ubiquitously 
expressed at a very low level in the cytosol under non-stressed conditions. However, 
the presence of excessive stress perturbations leads to CHOP induction and 
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overexpression of CHOP causes cell cycle arrest, decrease in Bcl-2 protein and 
eventually cell death [252]. We showed that H2
 We further examined the possible signaling mechanisms for the protective 
effect of H
S is able to down-regulate the 
elevated ER stress markers and hence protect cells from cell death. 
2
246
S against ER stress. Hu and colleagues have identified that both activation 
of ERK1/2 and Akt pathways play important roles in resisting ER stress-induced 
apoptosis signaling [ ]. Moreover, in previous studies, our group has demonstrated 
that H2 130S neuroprotection involves both Akt [ ] and ERK1/2 [209] pathways. In the 
present study, we investigated both Akt and ERK1/2 influences on H2S protection 
against ER stress. We found that inhibition of Akt pathway, but not ERK1/2, 
significantly increased the mRNA level of BiP and protein level of phosphorylated-
eIF2α when compared to the NaHS+6-OHDA group. Our results suggest that H2
 Hsp90 is one of the most abundant cytosolic proteins expressed in cells and it  
is an ATP-dependent molecular chaperone [
S 
exerts its protective effects against ER stress via activation of Akt but not ERK1/2 
pathway.   
253] that is essential for several cellular 
functions including cell signaling, protein degradation, assisting correct protein 
folding, assembly and maturation of client proteins [254]. The role of Hsp90 has been 
well-documented in maintaining cell proliferation and cell survival. Hsp90 may 
prevent apoptosis by binding to apoptotic peptidase activating factor 1 (APAF-1), 
resulting in inhibition of apoptosome formation and preventing activation of caspases 
and death [249]. Taiyab and team demonstrated that inhibition of Hsp90 leads to ER 
stress-induced apoptosis in rat histiocytoma [255]. Similarly, we showed that 
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inhibition of Hsp90 activity with Geldanamycin increased BiP mRNA expression. It 
is interesting to find that NaHS up-regulated Hsp90 protein expression. However, 
pretreatment with NaHS only reversed the ER stress induced by 6-OHDA, but not 
that caused by Geldanamycin. These data suggest that compared with the amount of 
Hsp90 protein level, its activity is more important in the neuroprotection  and H2
 Akt (PKB) is an Hsp90-dependent serine-threonine kinase that plays critical 
roles in the regulation cell proliferation, anti-apoptotic and cell survival responses 
[
S 
exerts its protective effect via Hsp90.  
256]. Akt-Hsp90 interactions is important as it has been proven that blockade of the 
binding to Hsp90 inactivated Akt and cells are more prone to apoptosis-inducing 
stimuli [256]. Hsp90 and Akt act synergistically with Hsp90 functions to balance and 
maintain the phosphorylation state of Akt [257] to promote cell survival. However, 
the effect of inhibition of Akt activity on Hsp90 is not known. Hence, by 
administrating Akt inhibitor and NaHS which has been proven to stimulate Akt 
activity, we proceeded to monitor Hsp90 level. Interestingly, we observed a decrease 
in the levels of Hsp90 molecular chaperone upon Akt activity inhibition. Our data 
suggest for the first time that activation of Akt by NaHS can elevate Hsp90 protein 
levels. However, we have to note that this Hsp90 elevation is not through gene 
expression modulation as we did not observe the elevation of mRNA level of Hsp90 
upon NaHS administration. Therefore, we postulate that H2S may have an impact on 
protein degradation. The mechanisms are still unknown and remain to be further 
investigated.   
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 It is worthy to note that in a previous study by Yang et al., H2
204
S was reported 
to induce apoptosis of insulin-secreting beta cells by enhancing ER stress [ ]. In 
contrast, H2
47
S was demonstrated in rats to attenuate HHcy-induced cardiomyocytic 
ER stess [ , 76] and stress-induced gastric ulceration [241]. Therefore, it is 
conceivable that different cell types have different sensitivity and reactions towards 
H2
The present observations identify the beneficial role of H
S. 
2S in protecting SH-
SY5Y cells against 6-OHDA-induced ER stress. The neuroprotective effect of H2S 
involves Akt-Hsp90 regulation. Our findings further suggest that H2
 
S may have 
potential therapeutic value in the treatment of neurodegenerative diseases such as PD. 
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CHAPTER 4 GENERAL DISCUSSION AND CONCLUSION 
 
4.1 General discussion 
The primary objective of this study was to examine the therapeutic effect of H2S in in 
vitro PD experimental model induced by 6-OHDA, a selective dopaminergic 
neurotoxin often used to establish PD model. Since H2
180
S synthesis was found to be 
disturbed in the brain of patients with PD [ ], AD [188], Down’s syndrome [258] 
and ischemic stroke [183], coupled with the recent evidences that H2
174
S produces anti-
oxidation [ ], anti-inflammation [143] and anti-apoptosis [173] effects in various 
neurodegenerative disorders experimental models, it is therefore reasonable to 
hypothesize that interaction of H2
In the present study, we used NaHS as the donor of H
S with PD is possible.    
2S to examine the effect 
of H2S on 6-OHDA-induced cell injury in SH-SY5Y cells. It was shown that 6-
OHDA decreased the cell viability of SH-SY5Y cells. Exogenous application of 
NaHS or the overexpression of CBS protected the cells against 6-OHDA-induced cell 
apoptosis and death via activation of PKCα, ε and PI3k/Akt pathways. This was 
further supported by other in vitro studies using PC12 and SH-SY5Y cells, showing 
that H2S protects cells against PD-generating neurotoxins 1-methyl-4-phenyl-
pyridium (MPP+ 173) and rotenone respectively [ , 202]. Proceeding on, our group 
administered H2S in animal models to determine its effect. In 6-OHDA and rotenone 
PD-induced rat models, it is found that H2S levels in both SN and striatum are 
reduced. Systemic administration of NaHS dramatically attenuated the progression of 
movement dysfunction and loss tyrosine hydroxylase (TH) positive-neurons in these 
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PD-induced rats [132]. In consistence with our reports, Kida et al. found that 
inhalation of H2
259
S reduced movement disorder and prevented the apoptosis of TH-
containing neurons and gliosis in nigrostriatal region in mouse model of PD induced 
by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [ ]. 
Therefore, all of these observations indicate a role of H2
 Formation of inclusion bodies and aggregation of misfolded proteins 
following neuronal loss in both familial and sporadic forms of PD [
S in the development of PD 
and its potential therapeutic value for PD treatment.  
106] have raised 
the possibility that ER stress is widely involved in the pathogenesis of PD. 
Upregulation of ER stress markers has been observed in postmortem brain tissues of 
PD patients [260]. In addition, we and other team have also demonstrated that PD-
induced neurotoxin such as 6-OHDA, MPP+
4
 and rotenone triggered the ER stress 
responses which contributed to neuronal cell death [ ]. Our group proceeded further 
to investigate the effect of H2S on 6-OHDA-induced ER stress in SH-SY5Y cells. We 
found that H2S reversed 6-OHDA-induced ER stress responses by down-regulating 
the up-regulated phospho-eIF2α, BiP mRNA level and CHOP protein expression and 
the H2
241
S protective mechanism involves Akt-Hsp90 pathway. In other diseases 
models such as rat models of stress-induced ulceration [ ] and of 
hyperhomocysteinemia (HHcy)-induced cardiomyocytic ER stress [261] as well as in 
cell culture of homocysteine (Hcy)-treated H9c2 [261], H2S treatment was also found 
to suppress the expression of various ER stress associated proteins. By contrast, H2S 
was reported to aggravate ER stress and induce apoptosis in insulin-secreting beta 
cells. Overexpression of CSE and exogenous application of H2S both stimulated 
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apoptosis of INS-1E cells and up-regulated the BiP and CHOP expressions via p38 
MAPK pathway [204].  The controversy on the role of H2S in ER stress may be 
attributed to several factors differing in the experimental studies. These factors may 
include the different sensitivity of cell line, the varying concentration of H2S used in 
treating the cells or that H2
 Notably, at present, endogenous H
S exerts different effects on different cell lines. 
2S lacks reliable measurement. Based on 
various group findings, physiological concentration of endogenous H2
179
S measured 
could vary from as low as nanoMolar [ ] to as high as microMolar [138, 140], 
making it difficult to determine a suitable therapeutic window for H2S treatment. 
Cheung and team demonstrated that at concentration of 30 µM, H2
262
S has already 
shown toxic effect on primary cultured neurons [ ]. On the contrary, our group 
showed that SH-SY5Y cells can tolerate H2 263S as high as 1 mM [ ]. Moreover, in 
our 6-OHDA-induced PD rat models, intraperitoneal (IP) injection of H2S at a 
concentration of 5.6 mg kg-1
252
 (100 µM) indicated protective effect without apparent 
adverse effect seen [ ]. Therefore, further investigation is needed to elucidate a 
suitable concentration of H2
 In the present studies, we demonstrated the protective effect of exogenous 
H
S in the central nervous system.      
2S against cell injury and ER stress induced by 6-OHDA in SH-SY5Y cells. 
However, the effects of endogenous H2S are still worth investigation. Recently we 
found that over-expression of CBS in SH-SY5Y cells efficiently reversed 6-OHDA-
induced ER stress (Data not shown). To elucidate the exact role of H2S in neuron 




 For most parts of the present studies, SH-SY5Y cells are used as a cellular 
model for dopaminergic neurons as it possesses many qualities of SN neurons. 
However, we noted that SH-SY5Y cells lack the expression of some neurotransmitter 
receptors such as NMDA receptor [262]. Moreover, as a immortal cell line, the 
vulnerability of SH-SY5Y cells to stress inducers is not comparable to those of 
neurons. Therefore, further studies to confirm our findings in these studies could be 
done on primary cultured neurons.           
 To date, some researchers have been focusing on the development of H2S-
releasing compound which can be delivered safely to the targeted system. Recently, 
ACS84, a hybrid molecule derived from L-Dopa and ACS50 (an H2S-releasing 
moiety) and other H2S-releasing derivatives have been developed. These drugs can 
penetrate blood brain barrier (BBB) and release H2S in the cells.  ACS84 and H2
264
S-
releasing NSAIDs were shown to suppress neuroinflammation and inflammation-
induced cell injury, elevate glutathione (GSH) level as well as inhibit monoamine 
oxidase B (MAO B) activity [ , 265]. Further investigation also suggested that 
ACS84 protected cells against Aβ-induced cell injury via attenuation of inflammation 
and preservation of mitochondrial function [266]. However, little was known about 
the mechanisms in which H2S was released from these compounds in the cells and 
more importantly, no solid evidence was found to demonstrate that the effects of 
these compounds were associated with the H2S released. It is also worthy to note that 
the effect of H2S or other H2S derivatives on other aspects of PD such as the 
occurence of Lewy's bodies has not been explored. Moreover, the physiological 
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relevance of the H2
 
S-generating enzymes such as CBS, CSE and 3MST in the 
progression of PD is yet to be determined. 
4.2 Conclusion 
The present study identifies the potential of H2S in protecting SH-SY5Y cells against 
6-OHDA-induced cell injury and ER stress. H2S shows promising neuroprotective 
role and may become a potential agent in treating PD. However, this is still a 
preliminary study and more in-depth researches are required. To date, the exact 
targeted site of action of H2S remains anonymous. Although various signaling 
pathways have been identified in H2S protection such as KATP, PKC, Akt, ERK1/2 
and p38 MAPK, the direct action site of H2S is still unclear. Therefore, knowing their 
precise site of action would help in determining if H2S is of therapeutic benefit for 
PD. With the vast variation of endogenous H2S measured ranging from as low as 
nanoMolar (nM) to as high as microMolar (µM), it is therefore also important to 
determine the H2S therapeutic window range. Apart from that, it is unknown if low 
concentration of H2S could exert possible side effects which include carcinogenesis. 
Also, investigations could be extended to the development of various drugs that 
release H2S at different rates to enable H2S to be delivered safely to the site of action 
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